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Abstract 
Bordetella pertussis is the causative agent of whooping cough (or pertussis) that has 
become resurgent worldwide. Resurgence has been linked to the introduction of acellular 
pertussis vaccines (ACVs) and the evolution of B. pertussis away from vaccine-induced 
immunity.  In 2012, the United Kingdom suffered a major pertussis outbreak. I conducted 
whole genome sequencing and genomic analysis of 95 strains including those isolated 
from the UK outbreak and demonstrated that although large-scale genetic changes in B. 
pertussis were not the cause of this outbreak, vaccine-antigen encoding genes are evolving 
at higher rates than other surface protein-encoding genes, this difference becoming more 
pronounced since the introduction of the ACV in the UK. 
The dramatic increase in the frequency of pertactin (Prn)-deficient strains worldwide is 
possibly in response to vaccine-mediated selection pressure. However, just one Prn-
deficient strain was identified among the UK outbreak strains. Prn expression and IgG 
binding to B. pertussis obtained with post-vaccine sera was determined by flow cytometry 
and compared between pre-outbreak and outbreak strains, but no significant differences 
were observed.  However, a positive correlation between Prn expression and post-
vaccination induced IgG binding to strains was identified, supporting the idea that strong 
immunological selection pressure is exerted on Prn and this is playing a role in the 
evolution of B. pertussis. The rapid evolution of vaccine-antigen encoding genes raises 
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1.1 Bordetella pertussis Infection and Disease. 
Bordetella pertussis is a gram-negative coccobacillus that is the leading cause of the 
respiratory tract disease whooping cough, or pertussis, in humans. Pertussis was a major 
global cause of mortality and morbidity, particularly in infants until the introduction of 
vaccination against pertussis resulted in a significant decrease in disease incidence among 
vaccinated populations. However, pertussis is still considered the leading cause of death 
among bacterial vaccine-preventable diseases, with approximately 140 000 reported cases 
and 89 000 deaths worldwide in 2014 (WHO, 2014).  Reported cases underestimate the 
true burden of disease with estimates of the actual number of annual cases numbering in 
the millions. During the last 10-15 years a number of countries have experienced a 
resurgence of pertussis despite continued high levels of pertussis vaccination raising 
concerns over the ability of vaccination to continue to control this disease. 
 
B. pertussis is acquired through infected droplets from other hosts. The bacteria display a 
strong tropism for the cilia of the respiratory mucosa and this represents the major site of 
infection (Paddock et al., 2008). Colonisation is followed by proliferation on the ciliated 
mucosal surface resulting in ciliostasis, damage to the respiratory epithelium, induction of 
mucus release and an inflammatory influx into the lumen of the respiratory tract. This 
initial stage of infection is characterised by mild symptoms similar to those of a common 
cold; including rhinorrhea, mild cough and sneezing. 
Infection typically progresses to the ‘paroxysmal phase’ characterised by the classic 
symptoms of pertussis including severe paroxysmal coughing. Paroxysms can occur 
multiple times each hour, every hour over several weeks leaving the host exhausted and 
gasping for air. This inhalation following coughing produces the distinctive ‘whoop’ sound 
of pertussis. The cause of paroxysmal cough during pertussis is unknown. For a long time 
pertussis was considered a disease only of infants and children but it is now recognized 
that all ages are at risk of infection, but that infants are at greatest risk of severe disease 
and death and in which complications are common including seizures and choking. A 
pause of breath leading to irregular breathing, known as apnoea, is more common in 
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neonates (Shojaei et al., 2014). Death is associated with pulmonary hypertension resulting 
in cardiac failure (Paddock et al., 2008), and occurs mainly in previously healthy infants. 
In these cases the combined effects of apnoea and pneumonia result in hypoxaemia which 
in turn leads to pulmonary vasoconstriction. The pronounced leukocytosis that is a 
hallmark of severe pertussis increases vascular resistance. The overall effect of these 
pathologies is pulmonary hypertension leading to cardiac failure and shock (Paddock et al., 
2008). 
Older children and adolescents also suffer pertussis. Anecdotally, pertussis in these age 
groups was described as milder than in infants. However, systematic study of disease in 
adults and adolescents reveals that disease resembling classic whooping cough is 
uncommon (Cherry and Paddock, 2014). It is probable that pertussis has been largely 
underestimated in this age category due to misdiagnosis (Masseria and Krishnarajah, 2015) 
and the true burden of disease in adults is uncertain. 
During convalescence coughing gradually subsides and bacteria are cleared from the 
respiratory tract by adaptive immune responses (see below). 	  
Table 1.1 Three stages of whooping cough infection	  
Stage of infection	   Pathology/symptoms	  
Catarrhal	   Adherence of bacteria to cilia, bacterial multiplication, 
resistance to clearance by innate immunity. 
Symptoms similar to those of a common cold. 
• Profuse and mucoid rhinorrhea 
• Malaise, fever, mild cough, sneezing and anorexia	  
Paroxysmal	   Cause of cough unclear, possibly due to pertussis toxin. 
Severe paroxysmal coughing, often followed by classic  
“whoop” on inhalation, breathlessness, exhaustion, 
vomiting, choking, breaking ribs 
• Life threatening in infants with underlying cardiac 
or pulmonary disease 
• Can lead to neurological complications 






1.2 Epidemiology and vaccination 
Gaining an accurate picture of B. pertussis epidemiology is difficult. Classically described 
whooping cough affects mainly infants and children, and thus the disease was considered 
to be one largely of childhood. Over time, it was realised that mild or atypical pertussis is 
common, and importantly, that B. pertussis is frequently detected in adults with chronic 
cough (Cherry and Paddock, 2014). Thus, B. pertussis is probably endemic throughout the 
population. Until the middle of the twentieth century pertussis was a major cause of 
disease in infants. During the 1940’s in the UK there were 980 000 notified cases (Fig 1.1), 
and in the same period in the USA there were an average of 175 000 cases per year (CDC, 
2015). The disease pattern was cyclical with peaks at 3-4 year intervals. The introduction 
of vaccination (see below) led to significant reductions in cases of pertussis. The changing 




Fig.1.1 Whooping cough notifications and vaccine coverage in England and Wales from the years 
1940-2010 Changes to the vaccine used, vaccine schedule and diagnostic methods used are shown. 





The first pertussis vaccines were developed during the 1930’s and implemented in most 
developed countries during the 1940’s and 1950’s (Cherry, 1996). These were whole cell 
vaccines (WCVs) comprised of chemically-killed bacteria. Often administered in 
combination with diphtheria and tetanus toxoids, a full primary course of vaccination 
comprised three injections. Japan started using a WCV in 1949, the Netherlands and 
Sweden began using the WCV in 1953 (King et al., 2013). The UK appeared reluctant to 
introduce vaccination. This probably stemmed from conflicting data regarding the efficacy 
of WCVs. Numerous different WCVs were available and there were significant differences 
in their composition and resulting efficacy. The development of a mouse intra-cerebral 
challenge model in which vaccination was protective allowed the development of measures 
of vaccine potency and standardization of WCVs. In 1957, the UK introduced a vaccine 
containing diphtheria, tetanus and whole-cell pertussis (DTwP) (Amirthalingham et al., 
2013). Initially vaccination was at 3, 5 and 11 months of age. Following the introduction of 
vaccination there was a very large reduction in the incidence of disease, demonstrating that 
WCVs were effective at preventing classic pertussis, i.e. whooping cough in infants and 
children, which was certainly the main recognised form of B. pertussis infection at that 
time. The introduction of vaccination globally has been a major success. Monitoring by 
WHO recorded around 140 000 cases of pertussis globally in 2014, resulting in 89 000 
deaths (WHO, 2014). Although this probably represents under-reporting it nevertheless 
signifies a tremendous reduction in disease burden compared to the pre-vaccination era. 
 
However, WCVs were considered ‘reactogenic’, causing side effects including fretfulness 
and injection site soreness and swelling. In particular more serious complications began to 
be associated with pertussis vaccination including seizures, other neurological sequelae 
and even sudden infant death, (Cherry, 1992). The evidence for and against ‘pertussis 
vaccine encephalopathy’ has been reviewed extensively (for example (Mattoo and Cherry, 
2005)). It is likely that the apparent linkage between infantile epilepsy, sudden infant death 
syndrome and pertussis vaccination is due to temporal association, with no cause and 
effect relationship.  This is similar to the measles, mumps, and rubella (MMR) vaccination 
and autism controversy in 2002 (Farrington and Miller, 2005).  Unfortunately a growing 
public distrust of the vaccines led to dramatic decreases in vaccination coverage. For 
example, in the UK coverage fell from 79% to 31% between 1973-8, contributing to a 
large-scale epidemic from 1977-1979 (Amirthalingham et al., 2013) (Fig.1.1) as well as a 
further two outbreaks in 1982 and 1985 (Baker, 2003). Eventually, public trust in the 
vaccine was restored when studies showed that the benefit from protection provided by the 
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vaccine outweighed its risks and disease returned to low incidence levels.  In 1990 the 
vaccine schedule changed to an accelerated schedule of 2-, 3- and 4-month primary doses 
to achieve protection against pertussis at an earlier age and to aid greater coverage with a 
full course of vaccination (Amirthalingham et al., 2013). 
 
Concerns about the safety of WCVs prompted the development of a second generation of 
pertussis vaccines, the acellular vaccines (ACV). These comprise 1 to 5 highly purified B. 
pertussis proteins: pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (Prn) 
and fimbrial proteins 2 and 3 (Fim2 and 3). A number of mono-, bi- and multi-antigen 
ACVs have been developed. The most commonly used contain either PT, FHA and Prn, or 
all five antigens, but all contain PT. Detailed reviews of these vaccines are available 
elsewhere (for example see (Decker and Edwards, 2000). Their efficacy to prevent 
pertussis appears to be slightly lower than that of WCVs, but they have better safety 
profiles than WCVs in terms of causing adverse reactions. Importantly, the immune 
responses stimulated by WCV and ACV differ, being Th1/Th17 biased vs Th2/Th17 
biased respectively (Ross et al., 2013). The consequences of this for host immunity-
pathogen interactions are unknown, but may have contributed to the resurgence of 
pertussis (see below). Initially introduced as booster vaccinations following primary 
immunisation with WCV, many developed countries switched to ACVs for the entire 
vaccination course at the end of the 1990’s and the early 2000’s. Much of the developing 
world continues to use the cheaper WCVs.  
During the 1990’s, a picture was emerging of waning immunity among adults being 
important for maintaining disease transmission. In the UK, there was concern that the 
accelerated primary schedule would lead to early waning of vaccine-induced immunity in 
pre-school years and transmission of pertussis from this age group to unvaccinated infants. 
When given as boosters, WCVs were very reactogenic. Thus, in 2001 in the UK, an ACV 
was used for the pre-school booster vaccination and from 2004, ACVs replaced WCVs for 
the entire vaccination schedule (Amirthalingham et al., 2013). It is estimated that 
switching from a three- to four-dose schedule provided 46% additional effectiveness (95% 
CI:7 to 71%) with effectiveness being 95.3% (95% CI: 91.9 to 97.2%) with monitoring for 
cases up to 7 years (Campbell et al., 2012). 
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1.3 ACV antigens, their role in pathogenesis and regulation of 
expression in B. pertussis 
1.3.1 Acellular vaccine antigens 
The antigens that comprise the ACVs are B. pertussis proteins selected due to their 
perceived role in Bordetella virulence. It was reasoned that induction of immune responses 
against these immunogenic proteins would target processes important for B. pertussis 
infection and thus prevent disease. Pertussis toxin is an AB5 exotoxin in which the B 
subunit (S2, comprising PtxB-E) binds to host cells to deliver the enzymatically active A 
subunit into the host cell. This subunit (S1, the PtxA protein) is an ADP-ribosylase that 
transfers ADP-ribose to host cell αi subunits of G proteins, inhibiting G protein activity. 
This allows unregulated adenylate cyclase activity increasing the intracellular 
concentration of cyclic adenosine monophosphate (cAMP) with subsequent interference 
with intracellular signaling. Many effects have been associated with the action of PT 
including a loss of electrolytes and fluids and secretion of mucus.  PT also reduces 
neutrophil recruitment to the site of infection (Andreasen and Carbonetti, 2008; Carbonetti 
et al, 2007). The overall effect of PT appears to be delayed recruitment of immune cells to 
the site of infection thus aiding the establishment of infection (Carbonetti, 2015). The 
remaining antigens have adhesin activity and are thought to enable B. pertussis to adhere to 
host cells and tissues during infection. Fimbrial antigens 2 and 3 (Fim2 and Fim3) form 
distinct fimbrial appendages from which the fimbrial tip adheres to sulfated sugars that are 
found throughout the mammalian respiratory tract (Geuijen et al., 1998).  Filamentous 
haemagglutinin (FHA) is a large, dominant adhesin involved in binding to the ciliated 
epithelium (Paddock et al., 2008) and evasion of complement (Jongerius et al., 2015).  
Pertactin (Prn) is an outer membrane protein of the auto-transporter class that mediates 
binding to human epithelial cells (Otsuka et al., 2012) as well as playing a role in resisting 
neutrophil mediated clearance (Inatsuka et al., 2010). 
 
1.3.2 The two-component virulence regulator 
BvgAS is a two-component system that is a global regulator of gene expression in B. 
pertussis (Cotter and Jones, 2003). Two component systems sense environmental stimuli 
and coordinate a response through the regulation of gene expression profiles. BvgS is the 
membrane sensor histidine-kinase, and BvgA is the partner phosphate-accepting response 
regulator. BvgS responds to environmental cues, which initiate a multi-step pathway 
leading to the phosphorylation of BvgA.  Upon phosphorylation, BvgA directly interacts 
with promoter regions of target genes whereby transcription of genes is initiated or 
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repressed (Willems et al., 1990; Chen et al., 2010; Kinnear et al., 2001). In B. pertussis 
BvgAS regulates the expression of approximately 1000 genes (A. Preston, personal 
communication) and in doing so directs B. pertussis between distinct phenotypes, a 
phenomenon known as modulation. Lacey (1960) was the first to detect this modulation in 
B. pertussis and identified three phenotypic phases: X mode, C mode and I mode, now 
known as Bvg+, Bvg– and Bvgi, respectively (Cotter and Jones, 2003).  
The Bvg+ phase is characterised by BvgA binding to the promoter regions of virulence 
genes to increase transcription and thus production of ‘virulence factors’ such as PT, 
fimbriae, adenylate cyclase and FHA involved in pathogenesis.  These virulence-activated 
genes (vag) can be classed as early- or late-activated genes (Jones et al., 2005), for 
example, ptxA-E (that encode the PT subunits) is classed as late activated, however, fhaB is 
classed as an early Bvg+ activated gene (Jones et al., 2005). The Bvg+ phase is active at 
37°C, the temperature of the human host. During this phase, BvgA also represses genes 
known as the virulence repressed genes (vrg).  It has been proposed that during Bvg+ 
phase, a gene designated bvgR (Bvg repressor), is activated by the Bvg system and 
transcribed, producing a repressor protein responsible for the binding at cis-repressive sites 
in the promoter regions of vrgs (Merkel et al., 1995, 1998). 
 The Bvg– phase is induced by a temperature change from 37°C to 25°C, or chemical 
modulators such as SO42- ions at 50mM or increased nicotinic acid concentration.  The 
Bvg– phase is characterised by the activation of virulence repressed genes (vrg) and 
reduction in expression of virulence genes, due to the absence of phosphorylated BvgA 
and the lack of expression of BvgR.  A definitive role for the Bvg– phase in B. pertussis 
biology is yet to be determined. It is not necessary for persistence of pertussis infection in 
the mouse model but may be required for effective infection (Martinez de Tejada et al., 
1998) via transmission and effective colonization, as studied in mice (Martinez de Tejada., 
1998; Locht et al., 2001). 
The third phase is Bvgi, an intermediate stage where the BvgAS system is neither 
completely activated or inactivated, and expression of other genes is induced such as bipA, 
encoding a putative outer membrane ligand binding protein, while a number of Bvg-
repressed and activated genes are not expressed (Stockbauer et al., 2001; Jones et al., 
2005; Decker et al., 2012).  Very little is known about this Bvgi phase, due to the overlap 
with both Bvg+ and Bvg– phases. However, in B. bronchiseptica, the Bvgi phase has been 
suggested to be involved in early stages of infection, biofilm formation and transmission 
(Decker et al., 2012; Irie et al, 2004;Vergara-Irigaray et al, 2005). Cummings et al (2006) 
used microarrays to compare the gene expression profiles of the Bvg+, Bvg– and Bvgi 
8 
 
phases of a B. pertussis clinical strain (GMT-1) and RB50, a B. bronchiseptica strain 
isolated from a rabbit.  There were 117 genes expressed only in the Bvg+ phase in B. 
pertussis GMT-1 genes, of which 71% were also expressed in B. bronchiseptica, 
suggesting the Bvg+ phase in both these species may have a similar role (Cummings et al., 
2006), and gives a strong indication that B. pertussis inherited this system from the B. 
bronchiseptica-like ancestor. Those genes found to be specific to B. pertussis Bvg+ phase 
included those encoding PT and its associated secretion system.  Contrary to this, the B. 
pertussis and B. bronchiseptica Bvg– phase shared very little similarity in gene expression.  
B. pertussis expressed a total of 34 Bvg- phase-specific genes, as opposed to 229 genes in 
Bvg- phase B. bronchiseptica.  Only 5% of these B. bronchiseptica genes were shared with 
B. pertussis.  These genes may have been lost during the evolution of B. pertussis as they 
may not have been required for survival in the human respiratory tract. B. bronchiseptica 
has a much wider host range and thus may need a wider variety of genes to be expressed 
for survival.  Two distinct classes of Bvgi phase were described in B. bronchiseptica, one 
class in which 69 genes were maximally expressed, and another in which 193 genes were 
maximally expressed. In contrast, for B. pertussis only 30 Bvgi phase-specific genes were 
identified, including bipA.  Cummings et al (2006) concluded that this Bvgi phase in B. 
pertussis was likely to have been inherited from its ancestor.  Cummings and colleagues 
(2006) also identified differences in gene expression between two B. pertussis strains, the 
laboratory-adapted Tohama I and GMT 1, highlighting the ability of B. pertussis	  to alter its 
phenotype, possibly in response to the different environment these strains occupy 
(laboratory and human, respectively). B. pertussis adopts the Bvg+ phase when grown at 
37oC and modulates to the Bvg- phase at growth temperatures below ca. 27oC. Thus it is 
often reported that B. pertussis will be in the Bvg+ phase within the human respiratory 
tract but it is not clear what the temperature of respiratory tract may be in individual hosts 
during the course of an infection. The upper airways are likely to be cooler than the lungs. 
Thus it is possible that Bvg activity may vary depending on the infection site in the 
respiratory tract. 
 
Additional mechanisms affecting B. pertussis virulence gene expression have been 
described. The promoters of fim2 and fim3 contain a homo-polymeric cytosine tract.  The 
length of this tract varies between strains of B. pertussis and it is proposed that the length 
of the tract can vary via slip-strand misparing during DNA replication (Willems et al., 
1990; Vaughan et al., 2014). Strains that did not express Fim3 had shorter tracts (by 1-5 
Cs) than those that did (Willems et al., 1990) suggesting that phase variation of fimbrial 
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antigens was determined by the length of the poly-C-tract.  In support of this, insertion or 
deletion of a C within the tract affected the binding capability and positioning of BvgA 
with respect to RNA polymerase (RNAP), (Chen et al., 2010).  Recently, Vaughan and 
colleagues (2014) analysed whole genome sequence (WGS) data from 22 UK clinical 
strains that enabled identification of the total population of poly-C tract lengths of each 
strain, and correlated this with the level of expression of Fim2 and Fim3.  Multiple 
populations with different polyC tract lengths of both fim2 and fim3 were observed within 
a single culture.  With this ability to alter the binding capabilities of BvgA, and the 
dynamics of the bvg system, B. pertussis has an incredibly efficient and effective process 
for inducing phenotypic fluidity and adaptation to its environment.  
 
1.4 Phylogeny and evolution of the Bordetellae 
1.4.1 The Bordetella species  
 The genus Bordetella comprises eight validly named species (von Wintzingerode et al., 
2001), and one that still awaits formal description, ‘Bordetella ansorpii’ sp. nov. (Ko et al., 
2005; Fry et al., 2007). The genome of at least one strain of each Bordetella species has 
been sequenced and thus comparisons of genome size and content are possible (Table 1.2) 
(Parkhill et al., 2003).   B. pertussis, B. parapertussis and B. bronchiseptica make up the 
“classical Bordetella” group and infect exclusively mammals.  B. bronchiseptica infects a 
wide variety of mammals, including swine, leading to atrophic rhinitis, and dogs causing 
kennel cough which can lead to pneumonia and death (Mattoo et al., 2005).  Bordetella 
bronchiseptica can also infect immunocompromised humans and cause respiratory 
symptoms, leading to death in some cases (Ner et al., 2003; Spilker et al., 2008; Garcia-de-
la-Fuente et al., 2015).  However, generally, B. bronchiseptica infections in humans are 
uncommon (Bjornstad and Harvill, 2005).  	  
Two lineages of B. parapertussis have been described, one isolated from sheep, and 
another from humans.  B. parapertussis can cause whooping cough but it is thought to be a 
more rare, and cause milder disease, than B. pertussis (Heininger 1994). Recent data have 
shown that B. parapertussis infections are more common than previously thought as 
Koepke et al (2015) found that B. parapertussis infections contributed to cases thought to 
be caused by B. pertussis during an outbreak of pertussis in Wisconsin.  As mentioned 
above, B. pertussis is strictly a pathogen of humans and has not been found in any other 




Not as much is known about the remaining Bordetella, although most have been isolated 
from humans.  Bordetella trematum has been associated with wounds, ulcers, ear infection, 
bacteraemia, fever and vomiting in humans (Vandamme et al., 1996; Saksena et al., 2015; 
Almagro-Molto et al., 2015), B. hinzii has been isolated from rodents, poultry and 
immunocompetent and immunocompromised humans, (Vandamme et al., 1995; Jiyipong 
et al., 2013; Palacián Ruiz et al., 2013; Hristov et al., 2012) and the two reports of ‘B. 
ansorpii’ involved isolation from an epidermal cyst and an immunocompromised host (Ko 
et al, 2005; Fry et al., 2007). Bordetella avium is an important bird pathogen that infects 
the upper respiratory airways and causes turkey coryza (Register & Yersin, 2005), and can 
infect humans (Harrington et al., 2015), but such reports are rare.  Bordetella holmesii has 
been isolated from the blood and nasopharynx of immunocompromised humans 
(Nijamkepo et al., 2000). Russell et al (2001) detected B. holmesii infection by DNA 
sequencing from an individual who had severe pulmonary fibrosis with pertussis-like 
disease. There are other reports of pertussis-like disease due to B. holmesii (Pittet et al., 
2014) but the incidence of B. holmesii infection is unknown. There have been reports of 
misdiagnosis of B. holmesii cases from USA, Canada and France.  Both B. holmesii and B. 
pertussis contain identical repeat elements that are targets for PCR-based diagnosis, thus 
infection from B. holmesii could have been mistaken for B. pertussis disease (Mazengia et 
al., 2000; Guthrie et al., 2010; Njamkepo et al., 2011).  Finally, B. petrii appears to be the 
only species of Bordetella that has been found in the environment such as soil, grass roots 
and marine sponges, as well as from the respiratory tract of patients including those with 
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Table 1.2. Genome size, mean G+C content and host of the nine Bordetella species 	  
Species	   Genome Size 
(Mbp) 
(approx.)	  
Mean G + C 
content (%)	   Hosts	  
B. holmesii	   3.8	   61.69	   Human	  
B. pertussis	   4.1	   68.12	   Human	  
B. parapertussis	   4.8	   68.43	   Human	  




B. parapertussis	   4.9	   68.15	   Ovine	  
B. hinzii	   4.9	   65.44	   Human	  
B. avium	   3.7	   61.58	   Turkey, human 
(rare)	  
B. trematum	   4.4	   63.55	   Human	  ‘B. ansorpii’	   6.2	   64.26	   Human	  
B. petrii	   5.3	   65.48	   Environment, 
human	  	  
 
1.4.2 Phylogeny and evolution 
Phylogenetic analysis using 16S rRNA gene sequences from the nine Bordetella species 
highlights their genetic relationship (Fig.1.2). B. holmesii is very closely related to B. 
pertussis as shown by previous observations (Weyant et al., 1995). The phylogenetic tree 
shows B. hinzii, B. avium and B. trematum as being closely related to each other and they 
may have arisen from a B. petrii-like ancestor. Gross and colleagues (2008) carried out 
sequence analysis of the genome of B. petrii and found proteins related to virulence of 
pathogenic bordetellae, as well as large genomic islands which may contribute to its 
metabolic ability in the environment.  Due to the ability of B. petrii to occupy both 
environmental and mammalian niches, it was suggested that this species could be the 
12 
 
intermediate evolutionary state between environmental and pathogenic bordetellae such as 
B. pertussis.   
 
1.4.3 B. bronchiseptica, B. pertussis and B. parapertussis: the ‘classical’ bordetellae 
The phylogenetic tree (Fig, 1.2) shows clustering of the “classical bordetellae”	  
(Diavatopoulos et al, 2005).  Ovine B. parapertussis clusters with the B. bronchiseptica 
strain isolated from a rabbit, as may be expected due to their non-human hosts.  The human 
B. parapertussis clusters near the human derived B. pertussis and B. holmesii strains. The 
dendrogram suggests that B. pertussis has diverged from B. bronchiseptica.   
 
Fig. 1.2 The genetic relationship between the nine Bordetellae species based on 16S rRNA gene 
sequences.  Tree was constructed in Seaview using PhyML.  Human B. parapertussis: Para_Hu.  
Ovine B. parapertussis: Para_Ov.  
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As noted in Table 1.2, the genome sizes of these Bordetella are distinct, with B. 
bronchiseptica having the largest of ca. 5.4 Mbp compared to B. parapertussis ca. 4.8 Mbp 
and B. pertussis ca. 4.1 Mbp.  Evidence suggests that B. pertussis and B. parapertussis 
evolved independently from a B. bronchiseptica-like ancestor via genome decay (Parkhill 
et al., 2003; van der Zee et al., 1997; Diavatopoulos et al., 2005).  In support of this, 
progressive gene loss over time from B. pertussis has been shown (King et al., 2010; Park 
et al., 2012).  This has been suggested as a way of adapting to the human host, by loss of 
genes not necessary for establishment in non-human environments, whilst retaining those 
essential for virulence (Bouchez et al., 2008). In B. pertussis gene loss and rearrangement 
occurs mainly via recombination between insertion sequence elements (ISE), specifically 
IS481 (Parkhill et al., 2003; Caro et al., 2006). IS481 comprises a 1 kilobase (kb) 
transposase gene flanked by repeats.  The Bordetella pertussis genome contains ca. 250 
copies of IS481, several copies of IS1002 and ca. 20 copies of IS1663.  In B. pertussis 
most of the sites of deletions and recombination are flanked by IS elements, evidence for 
their role in the evolution of the B. pertussis genome (Parkhill et al., 2003).	  
 
1.5 The genome and genetic diversity of Bordetella pertussis 
1.5.1 Genome 
Whole genome sequencing (WGS) has made it possible to conduct an in-depth, thorough 
analysis as a means of enhancing the understanding of the virulence, pathogenicity and 
evolution of the Bordetella species.  The first Bordetella genome project generated and 
analysed the genome sequences of a representative strain of B. pertussis, B. bronchiseptica 
and B. parapertussis (Parkhill et al., 2003), revealing species-specific genes.  B. 
bronchiseptica had more than 600 species-specific genes compared to B. pertussis and B. 
parapertussis, possibly reflecting its greater host range as a wider niche range is likely to 
require greater metabolic capacity and greater ability to respond to differing environments.  
B. pertussis had 114 species-specific genes, and B. parapertussis had 50 species-specific 
genes. However, it was later found that these genes were present in other B. bronchiseptica 
strains, suggesting that B. pertussis and B. parapertussis do not contain any species-
specific genes and have not undergone any gene acquisition during their evolution. 
 
1.5.2 Genetic diversity of B. pertussis 
Pre-genomics, the study of genetic diversity and epidemiological typing in B. pertussis was 
based on methods such as multilocus enzyme electrophoresis (MLEE), ribotyping, RAPD 
IS1002-based fingerprinting, variable number of tandem repeats (VNTR) and pulsed field 
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gel electrophoresis (PFGE) (Mooi et al., 2000; Advani et al., 2013; Van der Zee et al., 
1997).  Studies based on these methods found B. pertussis strains to be very highly 
conserved as well as appearing to have very limited genetic diversity when compared to 
other bacteria such as Escherichia coli, Streptococcus pyogenes and Helicobacter pylori 
(Go et al., 1996). Van der Zee et al (1997) conducted multi-locus enzyme electrophoresis 
(MLEE) on 18 B. pertussis strains from the Netherlands, USA and Japan and found the 
population structure to be largely clonal in nature, even though the strains were isolated 
from different countries. Advani et al (2013) carried out PFGE analysis of 396 strains from 
a number of European countries where different vaccine programmes were used as a 
means of determining the epidemiology and spread of B. Pertussis over a 10-year period. 
They found 5 common profiles that were dominant in these countries, suggesting that 
strains containing ‘successful profiles’ are able to spread to different countries and induce 
large shifts in the B. pertussis population.  Although methods like PFGE and MLEE are 
useful, they are somewhat insensitive, their capabilities to identify genetic relationships 
limited (van Gent et al., 2011) and they may detect only species diversity as opposed to 
strain diversity.  More recently whole genome sequence (WGS) analysis has become the 
gold standard for defining the true genetic relationships and diversity among B. pertussis 
strains over a period of time, due to its very high resolution.  The Tohama I genome is 
typically used as a reference genome. Once strains of B. pertussis are sequenced, the 
sequences can be mapped to this reference genome, and single nucleotide polymorphisms 
(SNPs) identified.  SNPs are defined as single base pair changes in the DNA sequence and 
are the most common form of genetic variation.  The SNP within a coding region will 
either be a synonymous mutation (SM), whereby the mutation does not change the amino 
acid sequence, also known as a silent mutation, or a nonsynonymous mutation (NSM), 
where the SNP alters the amino acid sequence, which may or may not alter the protein’s 
characteristics. SNPs found in non-coding regions such as promoter regions can affect the 
binding capabilities of RNA polymerase and transcription of genes.  Using SNP-based 
methods to identify genetic diversity between strains has been shown to be more effective 
than the traditional PFGE and MLEE methods, where false homoplasies in phylogenetic 
trees have been shown (van Gent et al., 2011).  Maharjan et al (2008) were the first to 
identify genome-wide SNPs, between an Australian B. pertussis strain and Tohama I.  
They used comparative genomic sequencing and identified 70 SNPs in a 1.4 Mb section of 
the genome.  They calculated the SNP rate of B. pertussis to be 1 SNP per 20,000 bp, 
confirming that the genetic variation in B. pertussis is incredibly low.  However, this study 
used only two strains and only one third of the genome was studied.  Further research by 
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Bart et al (2010) used 6 Dutch strains, two of which were isolated prior to the introduction 
of vaccination, and 4 strains isolated in 1999-2000.  This identified 471 SNPs.  They 
calculated a SNP density of 1 SNP per 8675 bases.  The location of these SNPs highlighted 
diversifying selection in more recent strains that are circulating in vaccinated populations 
compared to pre-vaccination strains.  Like Mahajan et al (2008), they concluded that B. 
pertussis has very limited genetic variation and is a highly monomorphic pathogen.   
 
The most definitive study to date was conducted by Bart and colleagues (2014) that 
conducted WGS analysis of 343 strains isolated between 1920-2010, from 19 countries, 
enabling the investigation of genetic variation of isolates worldwide, over time. 
This produced a phylogenetic tree based on the 5,414 SNPs found among the strains and 
identified two distinct lineages that diverged around 2000 years ago.  It was concluded that 
these two branches might reflect two separate introductions of B. pertussis in to the human 
host population.  There was very little geographical clustering of strains. An increase in 
genetic diversity of B. pertussis strains was observed following the introduction of the 
WCV, with more recent strains further diverging from the surviving lineage.  It was 
concluded that certain lineages of B. pertussis strains, especially those with a fitness 
advantage, spread rapidly across the globe.	  WGS analysis reveals that	  gene loss is ongoing, 
due to intragenomic recombination between IS481 repeats (Caro et al. 2006; Bart et al 
2014).	  
 
Recombination between IS481 elements not only cause deletions but also genome 
rearrangement (Parkhill et al., 2003). Gene rearrangement via insertion sequences plays a 
major role in the genetic and antigenic diversity of other species such as E. coli, where IS-
mediated rearrangements are reported to induce genetic variation (Drummelsmith et al., 
1997).  Research by Stibitz and Yang (1997) identified differences in gene order between 
laboratory-adapted B. pertussis strains.  Similarly, Park et al (2012) also identified 
considerable genomic rearrangements between Tohama I and another laboratory-adapted 
strain, 18323. Stibitz and Yang (1999) also found chromosomal rearrangements and 
inversions in clinical strains isolated from an outbreak in Canada (Stibitz and Yang, 1999).  
However at the time of the study the mechanisms behind this phenomenon was unknown. 
Later, research by Brining et al (2006) identified that most of the rearrangements were 
flanked by IS481 repeats hypothesizing that these IS elements may be responsible for some 
differences in gene order and transcript abundance between B. pertussis strains.  It was 
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concluded that B. pertussis used this mechanism to create genetic variation, in a species 
with very limited variation in gene repertoire.	  
 
1.6 The formidable hurdles to controlling pertussis 
1.6.1 Resurgence of B. pertussis	  
The introduction of the pertussis vaccine programme in the UK in 1957 proved extremely 
effective in reducing rates of pertussis morbidity and mortality. Prior to vaccination, the 
number of cases reached over 170 000 per year during the 1940s  (Fig. 1.1).  	  
However, over the last 20 years, numerous countries that have high pertussis vaccine 
coverage have suffered a resurgence of pertussis.  This includes France (Zepp et al., 2011), 
USA (Rohani and Drake 2011) and Australia (Octavia et al., 2012).  The Netherlands 
experienced a large-scale outbreak in 1996, when 2,771 cases were observed, compared to 
the previous year, in which only 319 cases were reported (de Melker et al., 2000).  From 
1996, cases of pertussis remained high with another resurgence reported between 2011 and 
2012 (van der Maas et al., 2013).  Similarly, California has experienced similar patterns 
with large-scale outbreaks of 9,000 cases in 2010, and again in 2014, with 9935 cases.	  
	  
1.6.2 The UK 2012 epidemic	  
Although vaccine coverage has remained ca. 95% in the UK (Health Protection Report,  
2015), in 2012, England and Wales experienced a large scale outbreak of pertussis 
(Fig1.3). A total of 9,711 laboratory-confirmed cases were recorded, leading to fourteen 
deaths in infants less than 3 months of age (Public Health England, Pertussis notifications 
and deaths, England and Wales: 1940 – 2014). This was much greater than the previous 
recent ‘peak’	  year in 2008, in which 902 cases were reported with 6 deaths in infants 
(Public Health England, 2014).   Thus the 2012 resurgence was considered ‘real’ because 
there was a marked increase in the number of deaths than what would normally be 
expected during the cyclic peak years.  Specifically, the number of cases began to rise 
towards the end of 2011 and peaked in October 2012 (Fig.1.3).  The highest number of 
cases was seen in the 15-40 year age group, a group that would have received the WCV. 
The reason behind the high number of cases in this group is considered due to the lack of 
boosting by natural exposure to B. pertussis strains because vaccine coverage was high 
during their time of birth (Amirthalingham et al., 2013).  Although the incidence has 
declined since the peak of 4621 cases in 2013 and a further reduction to 3388 cases in 2014 





Fig.1.3 The number of laboratory confirmed cases of pertussis in England and Wales from January 
2005 to March 2015 (Public Health England. Enhanced pertussis surveillance, 2014).	  	  
1.6.3 Changing epidemiology of pertussis resurgence. 
In countries experiencing pertussis resurgence, there has been a very noticeable shift in 
epidemiology (Clark, 2014). Historically, reported disease incidence has been highest in 
infants. Even after the widespread introduction of vaccination, although the numbers of 
cases decreased substantially, the 3-5 yearly peaks of disease observed in the prevaccine 
era remained. This suggests that although there was less disease, transmission of B. 
pertussis was not affected to the same degree. This situation remained until the late 1990’s 
and early 2000’s when the reported incidence of disease among adolescents began to 
increase. In outbreaks in the USA during 2004 and 2005, over 30% of cases were in 
adolescents (Clark, 2014). A further shift in epidemiology was observed during the USA 
2010 outbreak. Although the highest incidence of disease continued to be in the <1 year 
olds, significant levels of disease were observed among 7-11 year olds (Clark, 2014). In 
the UK outbreak in 2012, the highest incidence of disease was also in young infants but a 
large increase over previous years was also recorded in 10-14 year olds (PHE, 2015). 
These patterns describe a situation in which protective immunity from ACV vaccination 
appears to be waning earlier (see below), despite continued high levels of full vaccination 
coverage. The relatively-short lived immunity induced by ACVs is consistent with this 
epidemiological picture and has been the main focus of discussions around the use of 
booster vaccinations to halt this increase in disease among school-aged children. A further 




1.6.4 Asymptomatic infection. 
The epidemiology of B. pertussis has been largely defined based on the incidence of 
pertussis among different age groups. Additional studies have considered mild, or atypical 
disease by detecting B. pertussis among people presenting with chronic cough or other 
respiratory illness. While these have demonstrated that cases of B. pertussis infection are 
classic whooping cough, they do not address the issue of whether B. pertussis is present in 
apparently healthy people, i.e. whether B. pertussis can be carried asymptomatically. The 
recent findings made using the infant baboon model, described below, suggest that 
asymptomatic transmission occurs readily and given that the level and duration of 
colonisation of ACV-vaccinated baboons was greater than in animals vaccinated with 
WCVs (Warfel et al., 2014) it seems probable that asymptomatic infection has increased in 
humans where ACVs are used. Modeling of incidence data also supports the situation in 
which asymptomatic transmission is a major driver of the resurgence of pertussis in highly 
vaccinated populations (Althouse and Scarpino, 2015). This study predicts increasing 
numbers of asymptomatic infections following the switch from the use of WCV to the use 
of ACVs, and a subsequent increase in disease incidence. In addition, the advent of 
serology-based diagnosis has greatly increased the ascertainment of cases as blood samples 
are available from a wide range of cohorts. In all countries for which there are data, the 
incidence of seropositive samples greatly exceeds the reported incidence of pertussis 
disease, often by several orders of magnitude, and this was true for all age groups (Barkoff 
et al., 2015). It is not clear what degree of exposure to B. pertussis is required for 
seroconversion to a level counted as positive in these studies but as the incidence of 
seropositive samples was so much greater than the incidence of reported disease, it is very 
probable that asymptomatic infection accounted for a large number of positive samples. 
 
1.6.5 Management of the outbreaks 
Considering that the UK has a high level of vaccine coverage (Public Health England 
2014), the 2012 outbreak has become an area of increasing concern. Strategies have been 
put in to place to prepare for these outbreaks in the Netherlands such as an accelerated 
schedule of the vaccination program as well as the administration of an ACV pre-school 
booster usually given from 3 years 4 months, which appeared to reduce the incidence rate 
in both the 4-6 year old group and young infants when comparing the pre- and post-
implementation periods (van der Maas et al., 2013). However these measures had little to 
no effect on incidence rates in adults and adolescents, (van der Maas et al., 2013). 
Cocooning strategies have been used in California, involving vaccinating mothers and 
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fathers of new-borns as well as vaccinating pregnant women.  Efficient trans-placental 
transfer of antibodies from mother to babies has been observed (Gall et al., 2011; Leuridan 
et al., 2011) but whether or not these antibodies give direct protection against pertussis had 
yet to be established.  The importance of carrying out the above measures was highlighted 
by a study in Canada, France, Germany and USA.  Wendelboe and colleagues (2007) 
estimated that 76-83% of cases were from household members, demonstrating the 
importance of maternal vaccination and cocooning in controlling outbreaks.  In response to 
the national outbreak in the UK vaccination for pregnant women was offered from 1st 
October 2012, to protect infants from birth by inducing passive protection via the placenta. 
Antibody titres against the five vaccine components were measured in mothers who were 
vaccinated during pregnancy compared to those who were not in a case-control study 
(Ladhani et al., 2015). Initial results from case screening suggested that this approach is 
effective at protecting newborn babies (Amirthalingham et al., 2014) and this was further 
corroborated during a case-control study in which vaccine efficacy was estimated to be 
93% (95% CI: 81-97%) (Dabrera et al., 2015).	  
 
Due to the common occurrence of pertussis outbreaks across the world, pertussis has been 
named the most prevalent bacterial vaccine preventable disease worldwide which 
contributes to the consensus that pertussis is a resurgent disease that may no longer be 
effectively controlled by current vaccination programmes. 
 
1.7 Explanations for the resurgence	  
1.7.1 Is resurgence just greater awareness of pertussis disease?	  
Pertussis infections are reported following clinical diagnosis and/or laboratory 
confirmation by culture, PCR or serology.  PCR and serology are considered more 
sensitive than traditional culture-based diagnosis.  This together with greater awareness of 
pertussis could be a possible explanation for the increase in the number of cases recorded. 
However, despite diagnostic methods not changing from 2008-2012 in the UK, there was 
still a sharp increase in the number of cases in 2012.	  
 
1.7.2 The war of the vaccines	  
Another explanation for the outbreak is waning immunity. Natural infection by B. pertussis 
involves both cell-mediated and humoral responses (Higgs et al., 2012).  Upon infection, 
local macrophages, dendritic cells and neutrophils are the first responders to infection in 
the respiratory tract (Higgs et al., 2012).  Production of interferon gamma (IFN-γ) and IL-
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17 further enhances killing of B. pertussis by macrophage activation, suggesting that Th1 
and Th17 cells play a role in mediating the primary immune response (Higgs et al., 2012).  
The production of IgG antibodies occurs later during infection and is thought to play a role 
in complement fixing and opsonizing of bacterial cells to aid in clearance (Higgs et al., 
2012).   
 
Determining the efficacy and duration of ACV-induced immunity has become paramount 
to understanding global outbreaks.  As most countries have also used WCVs, comparisons 
between the efficacies of these two vaccines is possible. Several studies have indicated that 
vaccination with a whole cell pertussis-containing vaccine is associated with significantly 
greater protection than vaccination with solely ACVs (Sheridan et al., 2012; Witt et al., 
2013) however outbreaks have still been documented in Countries that have used the 
WCV, such as Canada (Bentsi-Enchill et al).  Furthermore, the composition and efficacy 
of the WCV has been shown to vary as a result of different manufactures and the strains 
used for the production of the WCVs (Gzyl et al., 2004). Several studies indicate that 
ACV-induced immunity is shorter in duration than WCV- or infection-induced immunity, 
resulting in those vaccinated with ACV being susceptible to infection at a younger age 
than those vaccinated with WCV (Rendi-Wagner et al., 2006; Warfel and Edwards, 2015; 
Witt et al., 2012). Acosta et al (2015) determined vaccine effectiveness in adolescents 
during the 2012 Washington state epidemic, after individuals completed the 6th pertussis 
vaccine-containing booster dose.  Two to four years post-vaccination, the effectiveness of 
the vaccine reduced from 73% to 34%. 
 
Qualitative differences in the immunity induced by ACVs compared to WCVs were 
demonstrated using a recently developed infant baboon model of B. pertussis infection and 
disease (Warfel et al., 2012). This model reproduces pertussis symptoms including cough 
for the study of B. pertussis infection biology. However, the ethics and logistics of the use 
of non-human primates limits study sizes and thus it is not possible to model factors 
operating at the population level as opposed to the level of the individual host. Animals 
were immunised with either a 5 component ACV or WCV at 2, 3 and 4 months of age and 
then at 7 months of age were intranasally challenged with B. pertussis (Warfel et al., 
2014).  Equal numbers of ACV-vaccinated baboons received either 3-component or 5-
component pertussis vaccines and the results were pooled. The baboons then underwent 
nasopharyngeal washes to quantify colonisation, in addition to monitoring of their 
symptoms.  The baboons vaccinated with ACV did not experience severe symptoms of 
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whooping cough, however, upon challenge, they failed to prevent colonisation by B. 
pertussis and were able to transmit the disease to other baboons.  Baboons vaccinated with 
the WCV had faster clearance of B. pertussis compared to those immunised with ACV.    
The T cell immunity of these baboons was also monitored and WCV-induced immunity 
mirrored that of a natural infection, demonstrating induction of B. pertussis specific T-
helper (Th) 17 memory cells and Th1 cells.  Baboons vaccinated with ACV mounted a Th1 
and Th-2 response, but no Th17 response, which is important for successful clearance. 
Thus, increasing evidence points to the failure of the ACV to sustain long-lasting 
immunity against pertussis as a key contributor to resurgence however not all Countries 
using the ACV have incurred a resurgence (Domenech et al., 2016). The WHO SAGE 
Working Group examined pertussis data from 19 countries and concluded that only 5 out 
of 19 countries (Australia, Chile, Portugal, USA and UK) supported the presence of a true 
resurgence. Chile was the only country that used WCV. Changes in other countries could 
not be separated from changes in surveillance systems and normal epidemic cycles. (WHO 
SAGE Working group report, 2014)  	  
1.7.3 Is B. pertussis evolving to evade vaccine induced immunity?  
The hypothesis that B. pertussis strains are evolving to evade vaccine-induced immunity 
has received a lot of attention. The ACVs comprise from 1-5 antigens and thus all selection 
pressure arising from vaccine-mediated immunity is targeted on these proteins and would 
likely select for mutations in their genes.  The allelic profile of the five vaccine antigen 
encoding genes in the vaccine strain Tohama I is ptxA2-ptxP1, prnA1, fim 3-1, fim 2-1 (Litt 
et al., 2009; van Loo et al., 2002) whereas many currently circulating strains harbour a 
distinct allele profile (ptxA1-ptxP3, prnA2, fim 3-2, fim 2-1), consistent with an increase in 
the selective pressures induced on these five antigens and subsequent allelic changes since 
the introduction of the ACV (Bottero et al., 2012; Elomaa et al., 2007; Komatsu et al., 
2010; Mooi, 2010). The expansion of these alleles in the population has been associated 
with the resurgence of whooping cough in the Netherlands, for example (Mooi et al., 
1998).  However these allele types have been dominant and circulating in the UK 
population since the 1990s  (Fry et al., 2001; Litt et al., 2009; Packard et al., 2004).  The 
non-vaccine types ptxA1 and prn2 have been circulating in the UK since 1984.  Thus, 
resurgence cannot be simply due to the emergence of variants displaying mismatches to the 




Variation in the ptx promoter (ptxP) has been identified as contributing to the resurgence in 
various countries. The ptxP is 266 base pairs (bp) in length and lies directly upstream of 
the start codon of the ptxA gene.  The ptxP allele in the vaccine strains is allele type 1 
(ptxP1) however up to 14 different alleles have been reported (Bart et al., 2014). In 
particular, the ptxP type 3 (ptxP3) has largely replaced other allele types and is by far the 
most dominant allele currently circulating worldwide (Kallonen et al., 2011).  PtxP3 is 
distinguished by a single base pair (bp) change from a guanine (G) to an adenine (A) 90 bp 
from the start codon of ptxA. The ptxP3 allele is associated with an increase in toxin 
production as more toxin has been shown to be produced in broth compared to ptxP1 
strains, and thus linked to the resurgence of pertussis (Mooi et al., 2009; Lam et al., 2012). 
The genetic background of ptxP3 strains also appears to play a role in fitness.  King et al 
(2013) demonstrated that ptxP3 strains colonized mice to higher levels than ptxP1 strains, 
but also, the genetic background of the ptxP3 strains improved overall fitness of the strains 
by increasing expression of other virulence genes suggesting ptxP3 has both a direct effect 
but is also a marker for other genetic changes influencing fitness (King et al., 2013).  
Advani et al (2011) studied the allele types of B. pertussis strains across two regions of 
Sweden using different vaccines.  During 1997-2006, the Gothenburg area, which used the 
mono-component (PT only) and the 2-component vaccine (PT and FHA) reported cases of 
whooping cough that were four times higher than other areas of Sweden.  A switch from 
ptxP1 to ptxP3 was identified in strains from the Gothenburg area, and was suggested as a 
possible reason behind the increase in the number of cases in this area. It was concluded 
that the difference in cases seen between the two Swedish areas could be explained by use 
of the mono-component vaccine in the Gothenburg area possibly accelerating the evolution 
of strains containing the ptxP3 allele, providing strong selection for strains producing 
increased amounts of toxin that might overcome solely toxin-focused immunity. The ptxP3 
allele is now the dominant allele circulating worldwide and it is believed this change in 
allele type is in response to vaccine-mediated pressure, with an increase in pertussis 
notifications associated with this switch (Mooi et al., 2009; Octavia et al., 2012; van Gent 
et al., 2012).  This allelic change may have a fitness advantage in the current B. pertussis 
population due to selection presssure.  The selective advantage of this allele type over 
other alleles such as ptxP1 has consequently enhanced its spread through the population.   
The study by Bart et al (2014) enabled a detailed study of effects of vaccination on 
population structure using strains from a 19 Countries.  Current outbreak strains have 
expanded from a lineage that arose prior to vaccination and have diversified since.  This 
was somewhat surprising as it was assumed that the introduction of the vaccine would 
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reduce genetic diversity, eradicating many clones with only those sufficiently mismatched 
to the vaccine strains surviving. Using Bayesian methods it was estimated that the ptxP3 
allele arose once during the WCV period, between 1974-1977 and subsequently spread 
worldwide. The fim2-2 allele arose during the WCV period and the WCV/ACV period, 
however the vaccine type fim2-1 allele has remained the dominant type worldwide. In 
contrast, the non-vaccine type fim3-2 has risen in frequency from 1% during the WCV era, 
to 37% in the ACV-era suggestive of a fitness advantage to strains carrying this non-
vaccine allele in the ACV-era (Bart et al., 2014).  Strains harbouring the ptxA1 allele 
increased in frequency from 1% frequency during the WCV period, to 90% in the ACV 
period. Thus, while it is likely that this allele arose prior to the introduction of vaccination, 
it is possible that the use of vaccines imposes a selective advantage on ptxA1 strains. Bart 
et al (2014) concluded that due to the lack of geographical clustering of B. pertussis 
strains, there is a rapid global spread of B. pertussis strains that appear to be evolving in 
response to vaccine driven immune selection, and thus, vaccine evasion.  This analysis 
highlights the large spread of B. pertussis strains at a global scale.  It identifies that 
transmission of B. pertussis is not limited within one country and that those alleles that are 
dominant are so worldwide.  The switch in allele type and successful spread in the 
population could possibly be in response to vaccine-induced immunity and it is 
hypothesized that these vaccine antigens are evolving to evade vaccine-induced immunity 
across the world.   
 
Much of the attention regarding vaccine-driven evolution of B. pertussis, and the most 
compelling evidence for it, stems from variation in prn. Prn contains two immunodominant 
repeat regions (Boursaux-Eude and Guiso, 2000), which are comprised of a glycine-
glycine-X-X-proline sequence and a proline-glutamine-proline repeat region, designated 
region 1 and region 2, respectively.  These repeat regions have been suggested to create a 
single discontinuous epitope recognised by vaccine antibodies (Hijnen et al., 2007).  The 
prn gene also encodes a tripeptide arginine-glycine-aspartic acid or RGD cell binding site 
motif, located directly before the first repeat region in the prn gene.  This RGD motif 
mediates cell attachment to a number of mammalian cells (Ruoslahti et al., 1996).  Further 
analysis of this motif suggested it also plays a role in the attachment to mammalian cells 
via integrins involved in uptake, as Prn-negative strains were observed to have a 30-40% 
reduction in attachment to Chinese hamster ovary cells compared to Prn-expressing strains 




Prn is thought to be a significant component of the acellular pertussis vaccine as the 3-
component vaccine containing Prn, FHA and PT was found to be considerably more 
efficacious than the 2-component vaccine containing just PT and FHA in a clinical study 
(Hewlett et al., 1997). The correlations between levels of antibodies to acellular vaccine 
components and protection against pertussis disease were studied after household exposure 
to B. pertussis in clinical trials in Sweden. The correlation between the levels of anti-
pertactin antibodies and antibodies against copurified Fim2/3 antigen and disease was clear 
and statistically significant (Storsaeter et al. 1998). Similar results were also reported by 
Cherry et al (1998) in a German household study. Furthermore, only anti-Prn antibodies, 
and not anti-PT, anti-FHA or anti-Fim2/3 antibodies, aid in phagocytosis of B. pertussis, 
providing a biological explanation for the correlation between protection and level of anti-
Prn titres (Hellwig et al., 2003).  A global collections of strains harboured 11 distinct prn 
alleles, which were characterised by polymorphisms in repeat regions (King et al., 2001), 
with the WCV era being dominated by the vaccine type prn1, which was eventually 
replaced by the prn2 and prn3 alleles, with prn2 dominating during the ACV period 
(65%). Anti-Prn1 antibodies do not bind to Prn2 or Prn3 as effectively, and monoclonal 
antibodies (mAb) directed against the epitope which harbours the polymorphisms are type-
specific (van Gent et al., 2011; King et al., 2001). This suggests that variation in Prn does 
affect recognition by vaccine-induced immunity. 
 
Of note, recently, a growing number of Prn-deficient B. pertussis strains are being isolated. 
Prn-deficiency arises from different mechanisms.  Insertion of IS481 or IS1001 into prn, 
an 84bp deletion at the start of the coding sequence, as well as a mutation at position 1479 
resulting in a stop codon have been reported (Otsuka et al, 2012; Lam et al, 2014; 
Hegerele et al, 2012).   
 
The prevalence of Prn-deficient strains varies between countries (Pawloski et al., 2014). 
Countries including Australia, Finland, France, Japan, and the USA have reported Prn-
deficient strains (Lam et al, 2014; Barkoff et al, 2012; Bouchez et al., 2009; Otsuka et al, 
2012; Pawloski et al., 2014). Zeddeman and colleagues (2014) investigated the frequency 
of Prn-deficiency in 261 B. pertussis strains from 6 European countries.  Prn deficiency 
arose several times independently, and the first countries to experience Prn deficient strains 
introduced the ACV much earlier than other countries where Prn-deficient strains are now 
starting to emerge.  Interestingly, Denmark has not reported any Prn-deficient strains. This 
country uses the mono-component ACV, which contains PT only. In the USA, Pawloski et 
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al (2014) investigated the frequency of Prn-deficient strains before and during the 2010 
California outbreak and the Washington State outbreak in 2012 and found the frequency of 
these strains had dramatically increased, with more than 50% of the strains being Prn-
deficient in 2012.  Furthermore, Martin et al (2015) carried out a retrospective study 
examining the relationship between Prn-expression by strains, vaccine history and clinical 
presentation in patients.  This showed that vaccinated individuals in the USA were more 
likely to have been infected with a Prn-deficient strain than a Prn-expressing strain. 
 
These data suggest that the introduction of the ACV may have exerted pressure on prn to 
evolve in order for strains to evade ACV-induced immunity.  As Prn has been shown to 
induce a protective immunity, possibly through high antibody titres, as demonstrated by 
vaccination studies (Higgs et al., 2012), the loss of this antigen could improve evasion 
from the host immune system in strains circulating in highly vaccinated human 
populations. Using the mouse model of B. pertussis infection it was demonstrated that 
naïve mice were colonized to the same degree by Prn-expressing or Prn-deficient strains. 
However, in mice immunized with ACV and then subsequently challenged with B. 
pertussis, Prn-expressing strains were cleared more quickly than Prn-deficient ones 
(Hegerle et al., 2014). Finally, a very recent study developed this further and assessed 
direct competition between Prn-expressing and Prn-deficient strains in the murine infection 
model (Safarchi et al., 2015). Coinfection of naïve mice and ACV-immunised mice with 
equal numbers of a Prn-expressing and a Prn-deficient strain revealed dramatic differences. 
In naïve mice the Prn-expressing strain became dominant by day 3 post-inoculation and 
accounted for over 90% of the B. pertussis recovered by day 14, demonstrating a distinct 
fitness advantage from expression of Prn in these hosts. However, in immunized mice, the 
reverse was observed, as the Prn-deficient strain accounted for over 90% of recovered 
bacteria by day 14 (Safarchi et al., 2015). Together these data strongly suggest that the loss 
of expression of Prn generates a fitness advantage to B. pertussis, but only in hosts 
immunized with an ACV. 	  
In summary, pertussis vaccines have proved highly successful in reducing the burden of B. 
pertussis and remain the best method of control.  However, due to the introduction of the 
ACVs, vaccine-mediated immune pressure is now focused on these five vaccine antigens 
in countries using these vaccines.  A worldwide resurgence of pertussis has been linked to 
switch to the use of ACV and the evolution of B. pertussis away from vaccine-mediated 
immunity. The fact that Prn deficient strains are increasing is good evidence to support the 
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hypothesis that strains are evolving to evade vaccine-induced immunity. However, 
resurgence is also associated with a rise in incidence in older age groups that were 
vaccinated using WCVs. This might suggest that adults have had greater exposure to B. 
pertussis in recent years or this could be further evidence for recent strains being able to 
evade vaccine-mediated immunity.  Further analysis of the UK 2012 pertussis outbreak 
will increase our understanding of the evolution and phenotypic behaviour of B. pertussis 
in the face of vaccine-induced immunity and help to provide reasons for pertussis 
resurgence.	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2 
Aims and Objectives  
 
Between 2011 and 2012, the United Kingdom experienced a large-scale epidemic of 
whooping cough. Therefore, the aim was to investigate whether or not the 2012 outbreak 
strains are evolving to evade vaccine induced immunity.   
In order to fully understand the reasoning behind this resurgence, identifying the 
evolutionary strategies and behaviours of B. pertussis is paramount.   
 
Whole genome sequencing was performed on 100 clinical strains of B. pertussis in order to 
investigate genetic differences between outbreak and pre-outbreak strains.  The specific 
questions were: 
 
• Do the 2012 outbreak B. pertussis strains form a single dominant clone that 
contributed to the resurgence?  
 
• Do the outbreak strains have an allelic profile that is specific to this group and 
could have contributed to the 2012 outbreak? 
 
• Are the vaccine antigen genes evolving at a faster rate than those coding for other 
surface localised proteins? 
 
The level of Prn expression was investigated in a panel of pre-outbreak and outbreak 
strains.  The specific question was: 
 
• Do the outbreak strains express a significantly different level of Prn that may have 
provided a fitness advantage in a highly vaccinated population? 
 
The same set of strains was also used to investigate differences in recognition by post-
vaccine sera.  The specific question was: 
 
• Are outbreak strains recognised at a significantly lower level than pre-outbreak 
strains? 
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3 
Materials and Methods 
3.1 Bacterial strains 
The genome of Bordetella pertussis Tohama I was determined by Parkhill et al (2003) 
(EMBL accession number BX470248) and was used as the reference genome in this study.   
100 B. pertusiss isolates were obtained from the National Reference Laboratory, 
Respiratory and Vaccine Preventable Bacteria Reference Unit at Public Health England 
(Appendix A). Five strains were collected between 1920-1956 (defined as the ‘pre-vaccine’ 
era), six strains collected between 1957-2000 (WCV era) and 89 strains were collected 
between 2000-2012 (ACV era). Serotyping was performed using sera specific for antigens 
1, 2, and 3 (89/596, 89/598, and 89/600, respectively; National Institute for Biological 
Standards and Controls, Potters Bar, United Kingdom) as previously described (Litt et al., 
2009). Tohama I (accession number BX470248), isolated in Japan in 1954, is widely 
studied and provides the reference genome sequence of B. pertussis (Parkhill et al., 2003). 
Tohama I is also used to manufacture Infanrix and Boostrix vaccines which are used in the 
UK.  
 
The genome sequence data of these strains have been deposited in the European 
Nucleotide Archive (http://www.ebi.ac.uk/ena/). 
 
3.2 Growth Conditions 
3.2.1 B. pertussis 
B. pertussis strains were stored at -80°C in PBS/20% glycerol stocks until required.  B. 
pertussis was streaked on to charcoal agar (Oxoid, UK) plates and placed in a 37°C 
incubator for 72 hours.  For broth cultures, B. pertussis was harvested from the plate, 
resuspended in 2ml PBS (Oxoid, UK) and the OD600 measured.  B. pertussis was grown in 
modified Stainer Scholte (SS) broth made at either Bath University (Table 3.1.a) with 
added supplements (Table 3.1.b) or Public Health England, Porton Down (Imaizumi et al., 
1983)  (Table 3.1.c & d). Cultures were inoculated to a starting OD600 of 0.1 and incubated 
at 37°C, with shaking at 180rpm. 
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Table 3.1a Components of Stainer Scholte (SS) broth prepared at Bath.  Components were 
dissolved in 90% of the final volume, adjusted to pH 6.7, brought to the final volume and 
autoclaved. 
Final 
concentration	   Chemical	   Amount to add to 1L (g)	  
 Casamino acids	   10	  
57mM	   L-glutamic acid 	   10.7	  
2.1mM	   L-proline	   0.24	  
43mM	   NaCl	   2.5	  
31mM	   KH2PO4	   0.5	  
2.7mM	   KCl	   0.2	  
0.49mM	   MgCl2.6H2O	   0.1	  
0.18mM	   CaCl2.2H2O	   0.0265	  










Chemical Amount to add to 
10ml (g)	  	  
0.33mM	   L-Cysteine	   0.04	  
36µM	   FeSO4.7H2O	   0.01	  
33µM	   Niacin	   0.004	  
0.49mM	   Glutathione	   0.15	  
2.3mM	   Ascorbic Acid	   0.4	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Table 3.1 c.  Components of SS broth made at PHE, Porton Down. Solution B, C and D are to be 
made separately then added to the final SS media (Table 3.2d).  
 
Solution B 
Ingredients Amount for 1 L Unit 
L-Cystine 12.5 g 
Concentrated HCl 222.5 ml 
Milli Q Water 777.5 ml 
  
Solution C 
Ingredients Amount for 1L Unit 
FeSO4.7H2O 2.5 g 
Milli Q Water 1000 ml 
 
Solution E 
Ingredients Amount for 1L Unit 
Nicotinic Acid 1 g 
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Table 3.1.d SS broth The first 12 (solid) ingredients were added to half total volume of water and 
stir to dissolve. Solutions B, C and E were added and then made up to the final volume.  The pH 
was adjusted to 7.6 and the conductivity checked.  The solution was then sterilsed by filtration. 
Ingredients Amount for 1L 











Ascorbic Acid 0.4g 
Difco casamino aicds 10g 
2,6 O-dimethyl beta 
cyclodextrin (Teijin Ltd 
Japan) 
1g 
Solution B 4ml 
Solution C 4ml 
Solution E 4ml 
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3.3 Genetic analysis of UK Bordetella pertussis strains  
 
3.3.1 DNA Preparation 
Genomic DNA extraction was performed using the Qiagen DNeasy Blood and Tissue kit 
according to the manufacturer’s instructions. 
 
3.3.2 DNA Sequencing and Single Nucleotide Polymorphism (SNP) Identification 
Twenty four isolates were sequenced previously (Bart et al., 2014). For the remainder, 
multiplex libraries, with fragment sizes between 300 and 500bp, were prepared as 
previously described (Harris et al., 2010) with modifications (Quail et al., 2012) and sent 
to the Sanger Institute for Illumina sequencing in October 2012.  Reads for each isolate 
were aligned to the Tohama I reference genome using SMALT version 0.7.4 
(http://www.sanger.ac.uk/resources/software/smalt/). Base calls were made as previously 
described (Harris et al., 2010), using a combination of samtools, mpileup and bcftools 
(Danecek et al., 2011), allowing SNPs, and small insertions and deletions relative to 
Tohama I to be identified. Five strains produced poor quality sequence and were excluded 
from the analysis, resulting in 95 strains being taken forward for analysis. 
 
3.3.3 Phylogenetic Analysis 
Maximum likelihood phylogenetic analysis was carried out on variable sites from across 
the whole genomes using RAxML under a GTR evolutionary model and a gamma 
correction for among site rate heterogeneity (Stamatakis et al., 2006). 100 random 
bootstrap replicates were run to provide support for relationships identified in the tree. 
SNPs were reconstructed on to the phylogenetic tree using parsimony. 
 
3.3.4 Analysis of SNP Densities 
SNP densities (SNP/bp) within vaccine antigen genes (9 genes: fhaB, prn, fim2, fim3, ptxA-
E) or ‘cell surface’ functional category genes (591 genes, as categorised previously 
(Parkhill et al., 2003)) were calculated by counting the number of SNPs per bp of each 
gene. The difference between the mean per gene SNP densities of vaccine antigen genes 
and cell surface genes was calculated. The significance of this difference was calculated 
using a non-parametric Monte Carlo simulation. In our randomizations of all the data, 
preserving relative sample sizes, it was observed how often a difference as large, or greater 
than the difference above was found, by repeated randomly resampling two samples of the 
same size as above. Using this protocol, if n is the number of observations that have 
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greater than or equal to the observed difference in SNP density and m is the number of 
simulations (in this case, 10 000), then P= (n+1)/(m+1) is the unbiased estimator. 
 
A similar procedure was used to compare SNP densities in vaccine antigen genes between 
eras. To account for differences in SNP densities between strains from the different eras, 
the SNP densities of the vaccine antigen genes were normalised by the SNP densities of all 
the genes considered (vaccine antigen and surface protein encoding genes). A non-
parametric Monte Carlo simulation compared the normalised SNP densities in the ACV 
antigen genes in ACV-era strains with pre-ACV era strains, with P determined as above. 
 
3.3.5 Allele Typing 
The different alleles of prn, ptxA, ptxP, fim3 and fim2 genes have been previously 
described (Mooi et al., 2010) and were used to identify allele types from DNA sequence. 
 
3.3.6 Analysis of prn from UK50 
The prn locus was amplified from UK50 by PCR using primers 5′-
CCGCTGATTCGCCACAAG-3′ and 5′-GTGCGGTACTTGCCCTTG-3′.  Primers were 
designed flanking the Prn gene sequence, ensuring that the full prn sequence was 
amplified.  This sequence was copied from the Tohama reference genome into a Microsoft 
Word document.  Potential primer sequences were identified by eye and the presence of 
SNPs in these regions were checked against UK50 to ensure efficient binding.  The Biolab 
TM calculator (http://tmcalculator.neb.com/#!/) was used to identify appropriate annealing 
temperatures as well as the GC content of the forward and reverse primers.  PCR products 
were cloned using the Gateway system (Invitrogen, Paisley, U.K.) and sequenced by 
Eurofins Genomics (Ebersberg, Germany) utilising standard M13 forward and reverse 
primers and internal primers 5′-GCGCACGCCTGTCCAAAG-3′ and 5′-
TAGCGAGCCAGCACGTAG-3′. 
 
3.3.7 Analysis of Differences in DNA Content Among Strains 
To detect gene loss from strains, compared to the DNA content of Tohama I, coverage 
plots generated using the paired end reads mapped to this reference genome were used to 
create a heat map. DNA sequence contigs that did not map to Tohama I were analysed 
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3.4 Detection of pertactin expression in clinical isolates of B. pertussis  
3.4.1 Formaldehyde killed B. pertussis strains	  
Due to the aerosol infection risk of analysis of live B. pertussis by flow cytometry, bacteria 
fixed by incubation in 2% formaldehyde for 1h were analysed. This protocol has 
previously been used for analysis of Fim expression (Vaughan et al., 2014).  B. pertussis 
was grown on charcoal plates and then grown in 50ml SS Porton broth.  The 50ml culture 
was then split in to two 25ml Falcon tubes (VWR), pelleted by centrifugation at 3000xg 
for 15 minutes and the supernatant discarded.  Pellets were resuspended in 25ml 2% 
formaldehyde and placed in a 37°C shaking incubator (180rpm) for one hour. Cells were 
pelleted by centrifugation at 3000xg for 15 minutes, the formaldehyde discarded, and the 
cells washed by resuspending in PBS.  Samples were centrifuged as above and re-
suspended in 10ml PBS.  100µl of the sample was inoculated onto agar plates and 
incubated at 37°C for 5 days to ensure all cells had been killed.  The sample was then 
divided into aliquots and stored at -20°C. It is understood that formaldehyde fixation may 
alter protein structure to some degree. Although this has not been confirmed for Prn, all 
samples received the same fixation treatment allowing quantitative differences between 
them to be observed.	  
 
3.4.2 Binding of anti-Prn Mab to B. pertussis measured by flow cytometry	  
In order to compare expression of Prn on the surface of B. pertussis, a 96 well plate assay 
was performed.  Two microlitres of anti-Prn monoclonal antibody, Pem#80 dated 
3/11/2010, 1.8mg/ml (a gift from Guy Berbers RIVM) was pipetted in to the designated 
wells of a 96 well plate.  198µl of formaldehyde-killed B. pertussis were then transferred 
to the wells at an OD600 of 1, which was done in duplicates for each strain. Plates were 
incubated at 25°C for 30 minutes with shaking at 190rpm, to allow binding of the 
monoclonal antibodies to Prn.  Plates were centrifuged at 3060xg for 5 minutes to pellet 
the killed bacteria and bound antibodies.  Goat FITC-conjugated anti-mouse IgG 
secondary antibody (Jackson Immunochemicals, 115-096-062) was added to the wells at a 
concentration of 1/500 and incubated for 20 minutes at 4°C to allow binding of the 
secondary antibodies to the anti-Prn monoclonal antibodies. Duplicate wells containing 
pelleted bacteria and secondary conjugate only were used as fluorescent background 
controls (C) to quantify non-specific binding of the secondary antibody. 
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The plate was centrifuged at 3060xg for 5 minutes, the bacteria washed using 200µl of 
2.5% bovine serum albumin (BSA) in Hanks Balanced Salt Solution (HBSS) and then 
centrifuged again.  The pellets were resuspended in 200µl of 2.5% BSA in HBSS.  	  
The fluorescence (FI) of each sample was read in the plates using the Beckman Coulter 
CyanADP flow cytometer at PHE Porton. The software used for analysis was Summit 4.3 
(Beckman Coulter, UK). The C value produced from the conjugate-only control wells was 
subtracted from the FI readings of the test wells (FI-C).	  
 
3.4.3 Binding of post ACV IgG to B. pertussis determined by flow cytometry	  
The procedure was the same as that above, however 2µl of post-vaccine sera (Table 3.4) 
were added to the wells instead of anti-Prn Mab.  Throughout the assays a range of 
different post-vaccine sera from different individuals was used due to the limited volumes 
available. Anti-human FITC conjugated antibody (Jacksons Immunochemicals, 109-096-
088) was used as secondary antibody.    	  
 
Table 3.4 Post vaccine sera and the date of extraction 
ID  Time post Repevax (ACV5) 
vaccination 
POST 4  1 month 
POST 7  5 months 
POST 9  7 month 
POST 13  1 month 
POST 14  1 month 
POST 2464  1 month 
POST 2669  1 month 
 
 
3.4.4 Statistical analysis  
 Comparison of Prn expression and post-Repevax recognition between historical (1920-
2011) and outbreak (2012) strains and ptxP1 and ptxP3 strains used an unpaired, two tailed 
t-test, assuming equal variance.  Correlation analysis (r) was evaluated using a Pearson’s 
product moment correlation coefficient.  The P values were determined using a table of 
critical values for r 
(http://www.radford.edu/~jaspelme/statsbook/Chapter%20files/Table_of_Critical_Values_
for_r.pdf).  The coefficient of variation (Reed et al., 2002) (SD ÷ FI-C x 100) was 




Genomic analysis of isolates from the UK 2012 pertussis 
outbreak reveals that vaccine antigen genes are 
unusually fast evolving	  
 
4.1 Rationale 
The resurgence of pertussis disease has been linked to increased surveillance, better 
diagnostic techniques and switching from the use of WCVs to ACVs. Also it has been 
proposed that vaccine escape mutants are arising, as ACV-induced immunity is focused on 
just a few antigens, and changes in these antigens might result in strains that are less well 
recognised by this immunity (Poolman et al., 2014).  
 
The frequency of different alleles of vaccine antigen genes among strains has changed over 
time (Bottero et al., 2012; Elomaa et al., 2007; Komatsu et al 2010; Mooi et al., 2010). 
The study of genetic changes in B. pertussis over time has been hindered by the high levels 
of homogeneity among B. pertussis and the lack of fine-resolution tools. Thus recently the 
genome sequences of a large panel of B. pertussis strains collected from around the world 
and across many decades were generated and analysed (Bart et al., 2014). This provided 
detailed information about the population structure and evolution of B. pertussis revealing 
significant genetic changes among strains over the last 50 years. However, this panel of 
strains did not contain isolates collected more recently than 2008, except for 3 isolates 
from the Netherlands collected in 2009 and 2010, and did not intensively sample a specific 
outbreak meaning that the genetic make-up of such events is largely unknown.  
Here 95 UK strains have been analysed with a focus on strains from the recent UK 
outbreak. B. pertussis strains were isolated from a number of locations across the UK, 
providing a sample of isolates with a relatively widespread geographical distribution (Fig 
4.1a).  The age of the patients that strains were isolated from varied however the majority 
of strains were isolated from young infants (Fig 4.1b). This is proportional to the number 
of isolates available for each age group, as the majority are obtained from hospitalised 
infants.   Sixty-one of the strains were isolated during 2012 and contained within the 
analysis, representing the most intensive genomic analysis of a single outbreak to date. 
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This will extend the previous analysis of Bart et al (2014).  The aim was to understand the 
clonal structure of the outbreak and determine if there was evidence for vaccine-mediated 
immunity driving the evolution of these strains. 
 
	  	   	  
Fig 4.1(a) Illustrates the geographical location of the isolation of UK B. pertussis strains used in 
this study as well as the age group of the patients from which they were isolated (b).  	  
 
4.2 Phylogeny of UK Strains from 1920-2012 
Phylogenetic analysis based on SNPs across the whole genome sequences was performed 
to understand the phylogenetic relationships between the UK strains (Fig. 4.2). Strains 
isolated during 1920-1982 form a cluster and are generally distinct from strains from 2008-
2012. The most distinct clustering separates strains carrying the ptxP1 allele from those 
carrying the ptxP3 allele, which, as found elsewhere, is the predominant ptxP type among 
recent strains.  A further more detailed phylogenetic tree was constructed showing the 
number of SNP differences between clusters of strains (Fig. 4.3).  This phylogenetic 
analysis was extended to place the UK strains in the global phylogenetic tree described 
elsewhere (please refer to Bart et al., 2014, Fig. 2 and supplementary text sd1, XLSX for 
the details of the global strains included in this phylogenetic analysis). This reveals that the 
UK ptxP3 strains separate into two clusters, distinguished by the presence of the fim3-2 
allele. The UK outbreak strains largely cluster with strains isolated mainly during the early 
2000s from a variety of geographical areas including North America, Europe and 
Australia.




Fig.4.2 Phylogenetic tree depicting the evolutionary relationships among the UK B. pertussis isolates studied.  Maximum likelihood phylogenetic analysis 
was performed on variable sites from across the whole genomes, using RAxML. Strains are shaded according to their year of isolation and ptxP type.
 39 
 
Fig 4.3 Phylogenetic relationships of UK strains within a global context. The UK isolated analysed 
here are indicated.   
 
4.3 Vaccine antigen allele profiles 
Previously, ptxP3-ptxA1-prn2-fim3-2 was defined as the dominant allele type circulating in 
the UK and other countries (Kallonen et al., 2009). Typing of alleles among the outbreak 
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strains reveal no recent change in this profile (Table 4.1). Numerous isolates deficient for 
the production of Prn have been reported in other countries, and a number of different 
mutations in prn responsible for this phenotype have been identified (Bouchez et al., 2009; 
Lam et al., 2014; Otsuka et al., 2012). It has been suggested that loss of Prn expression has 
been selected by vaccine-mediated immune pressure. Interestingly, just a single UK strain, 
UK50, was mutated for prn. This was identified by a lack of sequence reads mapping to a 
region of prn. The prn locus was amplified by PCR from this strain and the resulting 
product sequenced using Sanger sequencing. This identified that a recombination event 
between two copies of IS1663 has resulted in a deletion/insertion mutation in which the 5′ 
1326 bp of the prn coding sequence has been deleted. Aberrant mapping was not observed 
for any other UK strain. In other countries, a common prn mutation arose from insertion of 
IS481 into prn. Paired end reads were identified in which one read mapped within IS481 
but the other did not and thus derived from the region flanking IS481. Mapping these reads 
to the reference genome identified the position of the copies of IS481 within each query 
strain. No IS481 insertions into prn were identified among UK strains. This suggests that 
few Prn-deficient strains were involved in the UK outbreak. A small sample size, or 
skewed sample, will affect the number of Prn-deficient strains observed. However the 
strains analysed here represent strains isolated from numerous regions across the UK and 
from a number of different age groups. In other countries the frequency of Prn-deficient 
strains has reached more than 50% (Martin et al., 2015). It is clear that in the UK, Prn-
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*Prn allele type was determined for just 76 ACV era strains due to poor mapping of reads in this 
region in 8 strains. 
** Serotype was not determined for one ACV era strain, thus frequencies are based on 83, not 84, 




4.4 SNPs Specific to ptxP3 Strains 
PtxP3 strains are the predominant allelic type in current circulation and appear to have 
different infection biologies compared to ptxP1 strains. The ptxP3 SNP itself appears to be 
both a direct cause of these differences and a marker for other genetic variations that 
contribute to them (King et al., 2013). To investigate the genetic traits of UK ptxP3 strains, 
SNPs specific to this lineage were identified. In total, 22 such SNPs were identified (Table 
4.2). Ten were intergenic, seven of which were in the direct repeat region of IS elements 
which are present in multiple copies in the B. pertussis genome. It is not clear if these 
particular IS elements are functional. Twelve SNPs were in coding regions, of which, 
seven were non-synonomous mutations (NSM) and 5 were synonymous (SM). The 7 NSM 
were in genes within the “transport and binding proteins”, “pseudogene”, “conserved 
hypothetical”, “virulence-associated”, “regulation” and “unknown” functional categories 
as defined previously (Parkhill et al., 2003).   All of these SNPs were also identified 
among the global panel of B. pertussis strains (Bart et al., 2014). However, of the 22 SNPs 
identified here as being ptxP3-specific, only 10 were identified as being ptxP3-type-
specific in the previous study (Table 4.2), the other 12 SNPs were also identified among 


















Table 4.2. SNPs specific to UK ptxP3 strains. 
Locationa 
Typeb Mutationc Global 
ptxP3d 
Details 
36857 INT A:G Yes 93 bp upstream of BP0032 (encoding a 
putative transport protein), 156bp upstream 
of BP0033 (encoding GlyQ-glycyl-tRNA 
synthetase alpha chain) 
617083 
INT T:G No within the 5' repeat region of IS481 
(BP0611). 31bp upstream of transposase 
start codon. 
617084 INT C:T No within the 5' repeat region of IS481 
(BP0611). 32bp upstream of transposase 
start codon. 
1077844 
INT C:T No within the 5' repeat region of IS1663 
(BP1035). 139bp upstream of transposase 
start codon. 
1170424 INT A:G No within the 5' repeat region of IS481 
(BP1114). 31bp upstream of transposase 
start codon. 
1222400 INT A:C No within the 5' repeat region of IS481 
(BP1157).  31 bp upstream of transposase 
start codon. 
1635654 INT T:G No within the 5' repeat region of IS481 
(BP1557). 31 bp upstream of transposase 
start codon. 
2259917 INT G:C No within the 5' repeat region of IS481 
(BP2135). 98 bp upstream of transposase 
start codon. 
3263622 INT A:C Yes 193 bp away from BP3062. Putative integral 
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membrane transport protein. 
3988168 INT G:A Yes 89 nucleotides away from the start codon of 
ptxA.  ptxP3allele. 
196307 
NSM T:C  Yes BP0194. Putative transport protein. 
299559 
NSM  C:T Yes BP0292. Pseudogene. Conserved 
hypothetical protein. 
1331840 
NSM G:A Yes Pseudogene. BP1261. Hypothetical protein. 
1547488 
NSM A:G No BP1471. Conserved hypothetical protein. 
2374322 
NSM T:C Yes BP2249. BscI. Type III secretion apparatus 
protein. 
2651008 
NSM G:A Yes BP2502. Hypothetical protein. 
3134458 
NSM G:C No BP2946. Probable transcriptional regulator. 
185405 
SM  G:A  No BP0184. Putative periplasmic protein. 
518837 
SM  T:C No BP0507. Putative membrane protein.  
694521 
SM  A:G Yes BP0678. Putative peptide chain release 
factor.  
3840411 
SM  G:A Yes BP3630. RpsH. 30S ribosomal protein. 
3991376 
SM  C:T No BP3787. PtxC. Pertussis toxin subunit 
protein. 
a Tohama I reference genome coordinates (accession no. BX470248) . 
b Int: SNP is in an intergenic region. NSM: non-synonymous mutation, SM:  synonymous 
mutation. 
c e.g. C:T – C to T mutation. 





4.5 SNP Rates are high in Vaccine Antigen Encoding Genes 
Previously, it was identified that genes in the ‘cell surface’ functional category had higher 
SNP densities than the B. pertussis chromosomal average (Bart et al., 2014). However, 
ACV vaccine-mediated immunity is exerting selective pressure primarily on the proteins 
used in these vaccines and might be driving their evolution. To explore this, the SNP 
density (SNPs per bp) for the 9 ACV antigen genes (Ptx comprises five different proteins) 
and for the other 591 genes comprising the ‘cell surface’ category was calculated for all 
strains within each vaccine era and compared. Secondly, it was investigated if the SNP rate 
in ACV genes had increased since the introduction of ACVs.  The ‘cell surface’ category is 
considered the most compatible group of proteins for comparison work. They are exposed 
to the bacterium’s environment, including the host during infection, and thus will 
experience the same environmentally-derived selection pressures as the ACV antigen 
encoding genes except that they will not be subjected to ACV-induced immunity. Thus, 
differences in evolution between these two categories can be ascribed to ACV-induced 
selection pressure.   
 
The difference in mean SNP density across genes within the two samples (mean SNP 
density in vaccine antigen genes minus mean SNP density in cell surface genes) was 
calculated. A non-parametric Monte Carlo simulation was used to assess the significance 
of this difference by determining how often a difference as large or larger than this was 
derived by randomly resampling two samples the same size as above, from the pool of 
vaccine antigen and cell surface genes. This revealed that in each era, vaccine antigen 
encoding genes had significantly higher SNP densities than other cell surface genes 
(P<0.05, Table 4.3), with the difference being greatest among ACV-era strains. This 
suggests that the vaccine antigen genes are faster evolving than other surface protein 
encoding genes, and that they were also faster evolving even prior to the introduction of 
widespread vaccination.  
 
To compare SNP densities in vaccine antigen genes between eras, SNP densities within 
each era were normalised by dividing by the mean SNP rate across all of the genes 
concerned (ACV antigens and cell surface). In comparison to the prior analysis this has 
less power owing to the much smaller sample of ACV genes compared with total cell 
surface genes. Although the normalised SNP density in ACV-era strains was greater than 
in pre-ACV era strains, the difference was not statistically significant, P=0.160. However, 
the number of pre-ACV strains in this analysis was small. Thus, the same analyses were 
repeated using SNP data from the global collection of strains, for which the year of 
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isolation was known (Bart et al., 2014), and incorporating the UK strains sequenced here 
(see Table 4.3). Again, a significantly greater SNP frequency was found in ACV antigen 
genes than other cell surface genes, in all three eras. This time, there was also a 
significantly higher SNP frequency in ACV genes among ACV era strains compared to 
pre-ACV era strains (P=0.0177) suggesting that the relative SNP density in ACV antigen 
genes has increased since the introduction of ACVs. These results suggest that ACV genes 
are intrinsically fast evolving and provide some support for the hypothesis that they are 
even faster evolving since the introduction of ACVs. 
 
The more rapid evolution in the ACV antigen genes could be due to either a higher 
underlying mutation rate or different selection at the protein level.  The different selection 
could be positive selection or weaker purifying selection. To distinguish between these two 
possibilities, SNPs were split into SM and NSM. High NSM but not SM rates would 
suggest altered protein-level selection.  A higher rate of synonymous evolution (with 
possibly a weak non-synonymous effect) would suggest higher mutation rates.  
Interpretation here is difficult owing to well-described but incompletely understood 
correlation between synonymous and non-synonymous rates. 
 
Among WCV- and ACV-era global strains, but not pre-vaccine era strains, the SM 
frequency was significantly higher in ACV antigen genes compared to other cell surface 
genes, Table 4. When comparing ACV-era to pre-ACV era strains, the SM frequency in 
ACV antigen genes was significantly higher (P=0.004). NSMs also occurred at 
significantly greater frequency in ACV antigen genes compared to other cell surface genes 
(Table 4.4).  The magnitude of this effect is greater than that seen for SMs suggesting the 
higher evolutionary rate of ACV antigen genes compared to cell surface proteins is largely 
owing to protein-level selection on the antigens.  Evidence for a strong recent increase is 
less clear-cut. When comparing strains from the ACV-era to pre-ACV era strains, the NSM 
frequency in ACV antigen genes was on the edge of significance (P=0.051). Overall, these 
results provide support for the hypothesis that the genes encoding antigens chosen for 
ACVs are intrinsically fast evolving, in part owing to selection on their antigenic products. 
However, the possibility that in the ACV-era there has been an increase in the mutation 






Table 4.3. SNP rates in vaccine antigen encoding genes compared to other cell surface genes 
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2.91 x10-3 4.23 x10-4 2.49 x10-3 5.41 0.0001 
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Table 4.4. Synonomous (SM) and non-synonomous (NSM) mutation rates in vaccine antigen 
genes compared to other cell surface genes among strains isolated during the different vaccine eras.  
 
Vaccine era. 






















































4.6 Regions of Difference 
Deletions have been a major feature of B. pertussis evolution and appear to be on-going 
(Parkhill et al., 2003; Caro et al., 2008). Compared to the Tohama I reference genome, 
most of the major deletions observed among the strains analysed here had been identified 
previously (Caro et al., 2008). Numerous small deletions were found in only a few, or just 
one isolate, suggesting that deletion of DNA is common among B. pertussis strains. 
Interestingly, some deletions appeared specific to the UK ptxP3 strains, but no deletions 
specific to outbreak isolates were detected (Appendix B). 
 
Regions from individual strains that were not present in the Tohama I reference genome 
were investigated by BLAST analyses. These regions were also found within other B. 
pertussis genomes (BP18323 and CS), or in B. bronchiseptica RB50, similar to that 
reported in other studies (Kallonen et al., 2011).  Thus there were no novel insertions or 
gene acquisition among the outbreak isolates. 
 
4.7 Discussion 
The resurgence of pertussis in countries with high levels of vaccination has caused 
widespread concern. Among other factors, B. pertussis evolution away from efficient 
control by vaccine-induced immunity has been proposed as a contributor to this. Recently, 
whole genome sequencing was used to define global genetic variability among B. pertussis 
isolates and this identified genetic changes in the B. pertussis population over time (Bart et 
al., 2014).  
 
The genomes of UK B. pertussis isolates have been analysed extensively, with emphasis 
on strains from the 2012 outbreak. For the first time it has been shown that many 
genetically distinct B. pertussis strains contributed to this outbreak and importantly, that it 
was not due to the emergence of a novel, hypervirulent clone or expansion of an individual 
lineage. Furthermore, outbreak strains were genetically very similar to those circulating 
during periods when the incidence of pertussis was low.  There appeared to be no 
significant association between groups of strains holding particular SNP types and host age 
or geographical origin. The vaccine status was not known for all hosts, and thus it was 
difficult to investigate an association between vaccine status and these grouped strains.  
However those strains isolated from the unvaccinated one-month-old group, did not cluster 
on the phylogenetic tree, which suggests this lack of association.  
The ptxP3 type is dominant world-wide and UK outbreak strains are also predominantly of 
this type. Analysis of global isolates identified just 19 SNPs as ptxP3–specific (Bart et al., 
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2014). Here, 22 SNPs distinguished ptxP3 from ptxP1 strains. However, just 10 of these 
were common to both sets of ptxP3-specific SNPs. If ptxP3 strains have increased fitness 
or virulence compared to older isolates, the analysis here suggests that very few SNPs are 
responsible for this, or that particular combinations of SNPs are important, only some of 
which are ptxP3-specific. Overall, these data argue against large-scale genetic changes 
being behind the recent resurgence in pertussis. 
 
Changes in alleles of the genes encoding vaccine antigens have been well documented (for 
example, van Gent et al., 2012) and supports the hypothesis that selection pressure from 
ACV induced immunity is a driver of B. pertussis evolution. However, definitive studies to 
demonstrate that allelic variation enhances evasion of vaccine-mediated immunity are 
lacking and particularly difficult to perform given the inability to conduct studies with 
human hosts and that studies using animal models struggle to detect subtle changes and 
will not include population level effects that are certainly important for selection of 
variants among B. pertussis worldwide. Here, compelling evidence is provided showing 
that genes encoding ACV antigens are evolving more rapidly than other cell surface genes 
(which are considered the most suitable comparator group), containing a significantly 
higher frequency of SNPs in each of the vaccine eras. Interestingly, this was true even in 
the pre-vaccine era. It is likely that even in the absence of vaccination, the natural immune 
response to these antigens creates selective pressure, particularly for a pathogen that is 
restricted to the human respiratory tract.   Studies have shown this to be true of the 
Plasmodium falciparum whereby epitopes in proteins that interact with the immune system 
were under stronger diversifying selection (Krzyczmonik et al., 2012). 
 
Of particular importance is the calculation that ACV antigen gene evolution rates have 
increased significantly since the introduction of ACVs. This study is the first 
demonstration of this effect. This suggests that the use of ACVs has increased selection 
pressure on ACV antigens, selecting for ACV antigen gene variants. However, while the 
frequency of SM in ACV antigen genes was significantly higher in ACV era strains 
compared to older strains, the frequency of NSM was on the edge of significance 
(P=0.051). In turn this suggests that selection pressure from vaccine-mediated immunity is 
not the sole driving force for ACV antigen gene variation. A different interpretation is that 
the mutation rate of ACV antigen genes has increased since the introduction of ACVs. If 
synonymous sites are under weak purifying selection (i.e., not perfectly neutral), then there 
is a lag between a SNP arising and its elimination by this selection, resulting in an excess 
of SNPs in the modern era. However, normalising ACV gene SNP rates by the SNP rates 
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for all genes within the era largely eliminates this effect (i.e., SMs in cell surface genes 
should be equally over-represented in the modern era). However, if SMs in ACV genes 
and cell surface genes are under different intensities of purifying selection, then this result 
could be found. 
Either way, the more rapid evolution at the protein level (as determined by NSM) of ACV 
proteins compared to other cell surface proteins, across all eras suggests that strains will 
become increasingly mismatched to those used for vaccine production and this could lead 
to decreased vaccine efficacy over time. 
 
There are limitations arising from the sample sizes used here.  Very few older strains, 
particularly from the pre-vaccine era, were available and this limited the power of the 
analyses here, even though the difference in SNP rates between ACV antigen genes and 
cell surface protein genes was statistically significant. To counteract the limited strain 
collection available for UK strains, the analyses were expanded to include a global 
collection of strains. This expanded set of strains increased the power of the analyses and 
resulted in a greater significance of the results. Monte Carlo simulation was used here as it 
produces an unbiased estimation of probability. This approach requires no approximations 
as it uses only observed values and does not require assumptions of normality or even any 
assumptions about the distribution of data. Thus Monte Carlo simulation is considered to 
be the gold standard for unbiased estimations of ‘P’, and superior to other possible 
approaches. One issue with this approach is that it is likely to produce slightly different 
answers each time it is used on a dataset, due to the random sampling of the data involved. 
However, it is generally considered that performing sufficient randomisations eliminates 
this problem and 10 000 iterations is considered sufficient for this. 
 
Strains were assigned to one of three eras: pre-vaccine, WCV or ACV in an attempt to 
associate changes in evolution rates with vaccination and the type of vaccine used. There is 
not a clear cut-off between WCV- and ACV-eras as in most countries that use ACVs, there 
were several years in which the primary course of vaccinations were with WCV while 
ACVs were used as boosters. In the UK, both were in use from 2001 until 2004. However, 
just one strain, UK15, isolated in this period was included in this study and inclusion in 
either ACV or WCV eras does not affect the result of the analysis. 
It is perhaps surprising that such a statistically significant increase was observed in the rate 
of evolution of ACV antigen encoding genes in the ACV-eras compared to the WCV-era 
as it is a short time since the introduction of ACVs. However, the very recent sudden rise 
in the frequency of Prn-deficient strains has been taken as evidence of a strong ACV-
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induced selection pressure. Further analysis could subdivide strains in this ACV-era to 
compare the rates of evolution over time upon the introduction of these vaccines, with 
future analyses incorporating the most recent isolates. Care must be taken to consider the 
type of ACV used in different countries if using global data as some vaccines contain Prn, 
FHA and PT, whereas others also contain Fim2 and Fim3 (and in Denmark the vaccine 
contains just PT). It is clear that the ACV antigens are not a homogenous group as PT and 
FHA are secreted antigens, whilst Prn and Fim are integral to the outer membrane. 
However, they were selected for inclusion in ACVs in the 1980s based on their 
immunogenicity in the WCV and demonstration of protection in mouse disease models 
(Robinson et al., 1985).  The ACV antigens were chosen on the basis of their 
immunogenicity and it is likely that this property has driven the relatively high evolution 
rates of the genes encoding these antigens. These results raise fresh concerns over the 
ability of current acellular pertussis vaccines to continue to control disease.   
 
There is no doubt that the vaccine has provided a high level of protection and prevention of 
pertussis disease in the human population, however it has not succeeded in breaking the 
chain of infection by preventing transmission.   As a result, B. pertussis strains still 
circulate throughout the population, which is in contrast to other vaccine-preventable 
diseases such as diphtheria. Thus, it could be argued that evolution of B. pertussis strains 
away from vaccine-induced immunity is inevitable due to exposure to this selective 
pressure during circulation.  Globally, vaccination against pertussis varies, including the 
type of vaccine used and the schedule of vaccinations. Furthermore, different coverage 
levels are reached. This could lead to variation in the level of exposure of strains to 
vaccine-mediated immunity and thus variation in the rate of evolution in strains 
worldwide. As well as suggesting that B. pertussis evolution has accelerated since the 
introduction of vaccination, Xu et al (2015) found that the “molecular clock”	  of B. 
pertussis isolates varied between countries concluding that these differences might have 
been due to the variation in vaccine coverage and schedule between countries (Xu et al., 
2015).   
The results here indicate that the rate of evolution has increased upon the replacement of 
the WCV with the ACV, suggesting that the selective pressure on these antigens has 
intensified owing to the specificity of the ACV against these proteins. However there is no 
evidence that genetic changes caused the outbreak.  Phenotypic variation in response to 
selective pressure can take a number of years to accumulate and establish itself in a 
bacterial population before the effects are seen, as observed for the rise and spread of 
antimicrobial resistance.   Eleven years on since the introduction of the ACV in the UK 
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and six years in the infant schedule, a resurgence of pertussis was seen.  It could be that 
this is the number of years it has taken for these structural alterations to accumulate in the 
B. pertussis population before the affects are seen.   
 
Data suggest that vaccine-induced anti-Prn and anti-FHA antibodies provide the most 
opsonophagocytosis activity (Aase et al., 2011).  If strains are evolving to be recognised at 
a lower level by such antibodies, immune mechanisms such as opsonophagocytosis may be 
less effective.  Identifying differences in recognition between outbreak and pre-outbreak 
strains could highlight a possible fitness advantage in strains that were part of the 
resurgence in the UK.   
The increase in Prn-deficient strains is perhaps the best evidence for evolution and 
adaptation of B. pertussis strains away from vaccine-induced immunity, however only one 
Prn-deficient strain was identified in this UK collection.  To date no research has 
investigated different levels of Prn expression between strains, as a reduction in Prn 
expression may also provide an evasion strategy.  There are a number of mechanisms that 
could give rise to gene expression variation, SNPs being one of them.  However no 
mutations specific to the outbreak strains were seen in prn. Therefore, the next step of the 
thesis was to explore the expression levels of the Prn antigen and recognition level of 
strains by IgG binding of post-vaccine sera. 
 
The data presented in this chapter has been published in the Journal of Infectious Diseases 
and is included in Appendix C.     
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5 
Results 
Pertactin expression and IgG binding to B. pertussis 
using post acellular vaccine sera 
 
5.1 Rationale 
Pertactin is considered an important antigen of ACVs.  The large increase in Prn-deficient 
strains worldwide has led to the theory that this absence provides a fitness advantage to B. 
pertussis strains.  The genetic data from the UK B. pertussis clinical strains identified that 
only one was Prn-deficient, seemingly a much lower incidence than other countries 
experiencing resurgence. The recent increase in frequency of Prn-deficient isolates, and the 
demonstration that Prn-deficient strains have increased fitness compared to those 
expressing Prn in immunized hosts (albeit in a mouse model) fits with the hypothesis that 
avoidance of immunity directed against Prn is a selection pressure bearing on B. pertussis. 
An additional mechanism that might operate to avoid this immunity is a reduced level of 
expression of Prn, as opposed to Prn-deficiency. However, this has not yet been 
investigated. 
 
This chapter aims to test the hypothesis that in addition to Prn deficiency there are variable 
levels of Prn expression among strains, which results in variable levels of recognition of 
strains by antibodies in immune sera. 
 
5.2 Approach  
A panel of 2012 outbreak strains and historical (pre-outbreak) strains were selected 
encompassing a range of different SNP profiles and thus genetic variation as identified in 
the previous chapter.  The level of Prn expression by these strains and recognition by post-
vaccine sera was then measured.  Prn expression in B. pertussis strains was determined by 
a surface localised antibody assay.  Anti-Prn monoclonal antibody (Mab) was added to 
wells containing B. pertussis.  A secondary antibody conjugated with fluorescein 
isothiocyanate (FITC) was then added to form a complex with the anti-Prn Mab bound to 
Prn on the bacterial surface.  The resulting fluorescence of individual bacteria was 
measured by flow cytometry. Determining IgG binding to strains with post-vaccine sera 
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was performed using a similar assay. Individuals were vaccinated with the Repevax® 
booster vaccine, a 5-component vaccine containing the antigens Prn7, PtxA3, Fim 2/3 and 
FHA from the B. pertussis strain BP10536. Serum was added to the panel of B. pertussis 
strains, followed by the addition of anti-human Mab FITC conjugate.  The level of 
fluorescence minus the conjugate control (FI-C – see Materials and Methods), and 
therefore bound antibody conjugate, was quantified using a flow cytometer.  This FI-C 
reading indicated the amount of Prn on the surface of strains and bound post-vaccine IgG 
to the surface of the B. pertussis strains.   
 
5.3 Pertactin expression in clinical strains 
Pertactin expression was characterised by the binding of an anti-Prn Mab to formaldehyde 
fixed B. pertussis strains. All strains were prepared and analysed using the same protocol 
so that differences resulting from culture or sample preparation conditions were 
minimized. The well characterised laboratory-adapted strains Wellcome 28 and Tohama I 
together with Arg37, a Bvg- phase-locked variant of Wellcome 28 that expresses very low 
levels of vaccine antigens, was used as internal control strains.  Anti-Prn Mab binding was 
repeated on three separate occasions producing three datasets. The three datasets correlated 
well producing an R-value of 0.92, 0.89 and 0.86 when comparing dataset 1 with 3, dataset 
1 with 2, and dataset 2 with 3, respectively. As fluorescence values obtained varies from 
day to day data were normalized using values obtained using three strains common to these 
three experiments. The mean ratio of fluorescence values from these strains compared with 
experiment 1 was used to normalize data from experiments 2 and 3 to experiment 1 and the 
results are shown in Fig 5.1.  The coefficient of variation (Reed et al., 2002) (%CV) of Prn 
expression for strains that were repeated on separate occasions was calculated (Table 5.1) 
and these values are less than 35% which is acceptable for an antibody binding assay and 
was thus considered reproducible. The UK8 clinical strain isolated from 1979 showed the 
highest mean level of anti-Prn Mab binding, closely followed by UK3 (1946), UK39 
(2012) and UK48 (2012). A Prn deficient strain, UK50, was identified in the genetic data, 
which was confirmed in this assay.  This strain had similar levels of Prn expression to 
Arg37.  Due to the possibility that UK50 may have been Prn negative, it was not included 
in the statistical analyses of determining differences in Prn expression between strains 
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Table 5.1 The coefficient of variation (Reed et al., 2002) (%CV) of FI-C readings, which are 
directly proportional to Prn expression, in strains, which were analysed on separate occasions.  
Note a %CV value was not calculated for some strains as they were contained in one dataset only. 
 















Fig.5.3.1 The mean values of fluorescence of duplicate wells and the standard error bars of anti-Prn 
Mab binding to a collection of B. pertussis strains.  
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Differences in Prn expression between historical (strains previous to the 2012 outbreak) 
and outbreak strains (isolated from 2012) as well as between ptxP1 and ptxP3 strains were 
analysed using an unpaired, two-tailed, t-test and the data plotted in a Fig.5.3.2a & b 
respectively.  No significant difference was seen between historical and 2012 outbreak 
strains (p-value =0.26). However, there was a significant difference in the level of Prn 
antigen expression between ptxP1 and ptxP3 strains (p-value =0.01).  However, only two 
strains were in the ptxP1 group, compared to 17 strains in the ptxP3 group. Thus this data 
is preliminary and further analysis with more strains representing ptxP1 is required before 


















Fig 5.3.2a&b Box plot identifying the mean level of anti-Prn Mab binding to the surface of 
historical (1946-2011) and outbreak (2012) strains (a) and ptxP1 and ptxP3 strains (b).  
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5.4 Differences in recognition of outbreak and historical strains by post-vaccine sera 
Post-vaccine sera were used to investigate recognition of outbreak and historical strains by 
vaccine-induced antibodies (Fig. 5.4.1).  The experiment was repeated to test for 
reproducibility.  The correlation between the two sets of data was strong (r = 0.75, p-value 
= >0.001; Fig. 5.4.1). 
 
 
Fig.5.4.1 Correlation (r = 0.75) between the two sets of data used to detect the recognition of 
clinical strains by post-vaccine sera. A line of best fit is shown.  
 
Arg37, the Bvg-phase negative control, bound the lowest level of antibody (Fig.5.4.2) with 
a geometric mean of 36,818 FI-C. Tohama I, the laboratory-adapted strain also bound low 
levels of antibodies.  The Prn-deficient strain UK50 had the lowest level of anti-Prn Mab 
binding compared to the other clinical strains, at an FI-C of 61,529.  Those strains that 
bound the highest level of IgG were isolated in 2012 (UK48), as well as in 1946 (UK3) 
(Fig5.4.2).  The level of anti-Prn Mab binding appeared not to correlate with year of 
isolation (p-value =0.79) (Fig.5.4.3b).  Likewise, there were no differences in IgG binding 
with post-ACV sera between ptxP1 and ptxP3 strains (p-value =0.35) (Fig.5.4.3a).  UK50 
was not used in this analysis due to its likely Prn- deficiency. However, as stated above, 
the use of only 2 ptxP1 strains in this analysis makes any interpretation preliminary and 





















MFI – cj (Dataset one)
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Fig.5.4.2 The mean values of fluorescence obtained with duplicates of the 7 post-vaccine sera, comparing the quantity of IgG bound to the surface of each 
strain. The thick bold lines on each plot represent the geometric mean of all seven sera combined. Arg37 is a negative control and Tohama I is a positive 
control.












Fig 5.4.3a&b IgG in post ACV serum bound to and ptxP1 and ptxP3 strains (a) and historical 
(1946-2011) and outbreak (2012) strains (b)
Fig.5.4.3a 
Fig.5.4.3.b 
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5.5 Relationship between Prn expression and IgG bound to B. pertussis with post-
ACV sera 
 
The correlation between Prn expression and IgG bound to B. pertussis using post ACV 
sera was investigated.  Identifying a positive correlation between the two variables could 
suggest that anti-Prn antibody contributes to a large proportion of overall binding and 
variability in Prn expression could lead to variation in IgG binding with post ACV sera.  
Data from some strains that were used in the Prn expression studies have been omitted 
from these analyses because of failed readings on the flow cytometer when the post-
vaccine sera assays were performed. Therefore, only those strains where the coefficient of 
variation (CV) between duplicates was < 35% were included. A positive correlation 
between prn expression and recognition by post-vaccine sera (r =0.75, p-value = >0.001) 
was observed, and the line of best fit is shown in Fig.5.5.1. This analysis includes the Prn- 
strain UK50. If this is removed the correlation reduces to the weaker value r =0.46 (p-
value = 0.1). The relevance of this finding and the case for including Prn- strain in the 




Fig.5.5.1 Correlation between the level of anti-Prn Mab binding and IgG binding with ACV-
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5.6 Discussion 
The genetic analysis of the 95 UK strains established that many genetically distinct, but 
closely related strains contributed to the 2012 UK epidemic.  This argues against large-
scale genetic changes being behind the resurgence (see Chapter 4, page 36). Pertactin has 
received much attention due to the increasing numbers of Prn-deficient strains circulating 
worldwide.  Selective pressure from vaccine-mediated immunity has been suggested to be 
a driver for the emergence of Prn-deficient strains. Prn is classed as one of the key 
components of the vaccine as the level of antibodies against this antigen has shown 
correlation with protection in household contact studies (Storsaeter et al., 1999; Cherry et 
al., 1998; Olin et al., 2001; Higg et al, 2012), and thus the selective pressure on this 
particular protein may be strong, possibly stronger than other antigens contained in the 
vaccine, giving a possible explanation for the increasing number of Prn-deficient strains.   
 
The genetic analysis revealed one strain, UK50, to be Prn-deficient.  This was confirmed in 
this Prn expression study. It is not clear why only one Prn-deficient strain was identified 
among UK strains, as other countries have observed a far greater incidence.  It is possible 
that the sample size here was not a large enough to identify more Prn negative strains. 
However, the proportion of Prn-negative strains in other countries has been reported as 
high as >50%. Here, sixty-one 2012 strains were analysed, with just one Prn-deficient 
strain identified (1.6 %), suggesting that the incidence of Prn-deficiency is low. 
In previous studies, No attention has been given to the level of Prn expression in Prn-
expressing strains, thus the main focus here was to analyse potential differences in the 
expression level of Prn in outbreak and historical strains. 
 
Overall, the data did not indicate that Prn expression differed between historical and 
outbreak strains.  Similarly, post ACV serum antibodies bound to outbreak and historical 
strains at a similar level.  Therefore, it can be concluded that there is no clear phenotypic 
difference in Prn expression or binding of post ACV antibodies to the 2012 outbreak 
strains and historic strains. However, the significant difference in Prn expression between 
ptxP1 and ptxP3 strains is a very interesting observation. The anti-Prn Mab binding to 
ptxP3 strains was lower, albeit that only 2 ptxP1 strains were analysed.  This lower Prn 
expression could be a fitness advantage, in agreement with King et al (2013) who found 
that the genetic background of ptxP3 strains improved overall fitness and colonization in 
mice. In that study they showed that ptxP3 strains expressed a number of virulence genes 
at a higher level than the ptxP1 strains, but interestingly, prn was not one of them 
suggesting complex control of the expression of individual genes.  
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The positive correlation observed between Prn expression and post ACV IgG binding 
supports the hypothesis that lower Prn expression leads to reduced IgG binding with post 
ACV sera. This analysis included UK50, which lacks Prn expression. Although the 
concentration of anti-Prn IgG in the sera used in this study could not be obtained, the low 
level of post ACV IgG binding observed with this strain shows that anti-Prn IgG is an 
important component of opsonizing antibodies following ACV vaccination. This is perhaps 
unsurprising as Prn is the only integral membrane protein among the ACV antigens, with 
Ptx and FHA mostly excreted proteins. Also, the strains analysed predominantly express 
Fim3 only and the 5-component ACV has been shown to elicit a poor IgG response to 
Fim3 (Hallander et al., 2014).  This suggests that evolution of strains towards avoidance of 
vaccine-induced immunity involves avoidance of antibody binding to Prn. The appearance 
of Prn-deficient strains at high frequency is a recent phenomenon and fits with the switch 
to ACVs from WCVs increasing the immune selection pressure on Prn-expression among 
strains. The focus of this immune pressure is demonstrated by the importance of anti-Prn 
IgG for binding to B. pertussis shown here. In this study there is only weak evidence that 
decreased expression of Prn is evolving among recent strains perhaps suggesting that 
complete abrogation of Prn expression is required to produce a selectable fitness advantage 
in a population with high ACV coverage.  
 
Investigating the correlation between expression levels of the remaining four vaccine 
antigens Ptx, FHA, Fim2 and Fim3 and recognition by post-vaccine sera would enable 
comparative work in order to fully identify the extent to which anti-Prn antibodies 
determine overall recognition of bacteria by vaccine-induced antibodies. Before any 
comparisons between these five antigens could be made however, identifying the antibody 
titers of anti -Ptx, -FHA, -Prn, -Fim2 and -Fim3 IgG in patient sera would be necessary.  
However due to time and money constraints, this was not possible. 
 
In summary, the phenotypic data thus far have not identified a level of Prn expression or 
vaccine IgG binding that is specific to the 2012 outbreak strains. The finding that binding 
by post-ACV IgG and expression of Prn antigen have a positive relationship is a very 
interesting observation and provides further evidence that vaccine-induced antibodies are 
playing a role in the evolution and evasion of B. pertussis strains in vaccinated 
populations.  




The data from this project argue against large-scale genetic changes as a contributor to the 
UK 2012 pertussis resurgence.  Ongoing genetic drift in B. pertussis strains is a major part 
of its evolution (Xu et al., 2015).  Data have shown that there are generally a number of 
distinctive genetic profiles present at any one time and such profiles are on-going 
(Cassiday et al., 2016).   In light of this, the lack of a distinctive clone in the 2012 outbreak 
panel is not surprising.  However, this project identified that the genes coding for the 
vaccine antigens are evolving at an accelerated rate, which was further increased upon the 
introduction of the ACV.  This supports the hypothesis that strains are evolving to evade 
vaccine-induced immunity and similar studies have identified the evolution of B. pertussis 
is closely associated with vaccine coverage (Xu et al., 2015). The rapid increase in the 
frequency of Prn-deficient strains is perhaps the best evidence that B. pertussis are 
evolving away from vaccine-induced immunity. Furthermore, Prn deficient strains have 
shown better fitness in vaccinated mice (Hegerle et al., 2014; Safarchi et al., 2015), 
suggesting the evolution of Prn negative strains could improve the survival and 
transmission capability of B. pertussis in vaccinated populations.    
However, only one Prn-deficient strain was identified in this collection, which could be 
due to the later introduction of the ACV in this country, the relatively low numbers of 
vaccine doses in the UK schedule compared to some other countries or that this vaccine is 
a 5 component, while others are 2-3 component, so the immune pressure is spread across 
more surface-associated antigens.  The level of expression of Prn in outbreak and pre-
outbreak strains was investigated, but no significant differences were observed to suggest 
that strains isolated during the outbreak had lower levels of Prn expression.   Similarly, 
there were no significant differences between pre-outbreak and outbreak strains in their 
recognition by post-vaccine sera.  However, this experiment should be repeated using a 
much larger panel of B. pertussis strains to gain a better perspective on the dynamics of 
immune recognition from strains isolated from different years.  Unfortunately, due to time 
and funding, this was not possible. 
Although further work is needed on the observation that ptxP3 strains expressed 
significantly less Prn than ptxP1 strains, work by Bouchez et al (2015) identified a 
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significant reduction in the transcription level of prn in ptxP3 strains compared to ptxP1 
strains, adding weight to the observation seen in this thesis.   
 
The finding that there was a positive correlation between Prn expression and recognition 
by post-vaccine sera suggests that anti- Prn IgG is a significant component of vaccine-
induced responses.  This is obviously desirable for a vaccine, but also increases selective 
pressure on this antigen to evolve towards evasion, which appears to have occurred in B. 
pertussis.   The findings also highlight the effect Prn deficient strains have on the ability of 
post-vaccine sera to recognise and bind to the surface of B. pertussis strains, adding 
support that prn deficient strains could have survival advantage in a vaccinated population.   
 
In conclusion, this project has provided evidence that the genes coding for vaccine antigen 
proteins are evolving to evade vaccine-induced immunity, and the introduction of the ACV 
has accelerated this affect, not only in the UK, but worldwide.  This could have serious 
consequences for the ability of the current acellular vaccines to continue to control 
pertussis.  




A number of interesting observations have been made in this project, some of which has 
produced preliminary work and providing a good basis to work on. 
 
The data in Chapter 5 identified a positive correlation between Prn expression and 
recognition by post-vaccine sera.  However adding a larger panel of strains to carry out this 
experiment would gain a better perspective on the dynamics of Prn expression and immune 
recognition.  It would be worthwhile also including post-WCV-sera to see whether or not 
the same correlation is seen.  It could be hypothesised that the positive correlation between 
post-WCV-sera and Prn expression would be weaker, due to the reduction in specificity of 
antibody recognition to antigens, supporting the view that the ACV has increased the 
selective pressure and therefore evolution of B. pertussis strains away from the vaccine 
type.   
Follow up work on identifying differences in Prn expression between ptxP1 and ptxP3 
strains would also be pursued as only two ptxP1 strains were used in the current study.  
PtxP3 strains are the dominant type circulating in worldwide and have shown increased 
fitness (King et al., 2013).  Furthermore, Bouchez et al (2015b) identified a significant 
reduction of prn transcription in ptxP3 strains compared to ptxP1.  Understanding how this 
phenotype survives in a vaccinated population is important in recognising the reasons 
behind the resurgence seen.  
 
Investigating other mechanisms of genetic variation in B. pertussis would be appropriate to 
pursue. 	  	  The possibility of gene rearrangements playing a role in phenotypic plasticity 
could be likely, given that B. pertussis harbours ~240 copies of IS481 which is known to 
play a major role in the evolution of B. pertussis.   It is well documented that changes in 
the location of genes in the genome can affect the level of transcription, and expression 
profiles of genes (Sousa et al., 1997). Highly expressed genes are found on the leading 
strand of the genome (Price et al., 2005), but if these genes are then moved to the lagging 
strand, their expression is lowered.  Similarly, if genes move further away from the origin 
of replication, for example those involved in Bvg modulation, this will also affect gene 
expression, which will lead to variation in phenotype.  A single previous report identified 
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significant differences in transcript abundance between B. pertussis strains and also within 
the same strain as a result of genome rearrangements (Brinig et al., 2006).	  
In B. pertussis genome rearrangements occur by recombination between IS481 elements 
(Parkhill et al., 2003). Resulting rearrangements of the genome could affect gene 
expression and thus the physiology of strains.   Recently, a new sequencing system (Pacific 
Biosciences (PacBio)) has become available which produces long sequence reads (>5kb) 
that can span the IS481 repeats in B. pertussis genomes.  The Sanger institute performed 
PacBio sequencing on 5 clinical UK B. pertussis strains used in this thesis, which revealed 
a high level of genome rearrangements (Fig. 8.1) that were flanked by IS481 elements.   As 
part of the further work using the PacBio system, it would be worth further investigating 
genome rearrangements which could reveal a previously unrecognised variability among 
B. pertussis, which had been previously thought of largely as a single, homogenous entity.   
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Fig.8.1. Alignment of the genome sequences of 6 B. pertussis strains reveals extensive variation in genome arrangement (A. Preston pers comm). Tohama I is 
the reference genome sequence produced by Sanger sequencing. The other five strains were sequenced using the PacBio platform. Assembly of data produced 
a single sequence contig for strains UK16, 51 and 69; but 5 contigs for UK 2 and 7 contigs for UK1 (shown by red lines in the alignment). Sequences were 
aligned using Mauve. The origin of replication is at coordinate 1 in each sequence. The different coloured segments are colinear regions of the genomes. 
Regions above the horizontal line are sequences of the plus DNA strand, below the line are on the minus strand. The relative position of colinear blocks, and 
the strand on which they located varies between strains indicating inversions and translocations have occurred within the genome of each strain. 	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Metadata of Tohama I and the UK clinical strains used in this thesis. 
 






Isolation	   Serotype	   ptxP	   ptxA	   prn	   fim2	   fim3	  
Tohama	  I	   	  	   BX470248	   Japan	   1954	   1,2	   1	   2	   1	   1	   1	  
UK01	   NCTC10901	   ERS018345	   St	  Mary's	  Hospital,	  London	   1920	   1	   1	   2	   1	   1	   1	  
UK02	   CN0141	   ERS018346	   Hampstead,	  London	   1942	   1,2	   1	   2	   1	   1	   1	  
UK03	   CN1407	   ERS018347	   Oxford	   1946	   1,2,3	   1	   2	   1	   1	   1	  
UK04	   CN2055	   ERS018348	   LSHTM,	  London	   1947	   1,2	   1	   1	   1	   1	   1	  
UK05	   CN3001	   ERS018349	   CPHL,	  London	   1949	   1,3	   1	   2	   1	   1	   1	  
UK06	   NCTC10910	   ERS018350	   PHL,	  Coventry	   1967	   1,2,3	   1	   1	   1	   1	   1	  
UK08	   MANCH8002	   ERS018349	   PRL,	  Manchester	   1979	   1,2	   1	   1	   1	   1	   1	  
UK09	   DCH039	   ERS018350	   CAMR,	  Salisbury	   1982	   1,2	   1	   1	   3	   1	   1	  
UK10	   DCH088	   ERS018353	   CAMR,	  Salisbury	   1982	   1,2,3	   1	   1	   1	   1	   1	  
UK11	   DCH166	   ERS018354	   CAMR,	  Salisbury	   1983	   1,3	   1	   1	   1	   1	   1	  
UK14	   98K323	   ERS018355	   Aberystwyth	   09-­‐Nov-­‐88	   1,2	   1	   1	   1	   1	   1	  
UK15	   BP0865	   ERS018356	   Birmingham	   02-­‐Aug-­‐02	   1,3	   3	   1	   2	   1	   2	  
UK16	   H060580043	   ERS018357	   Slough	  
February	  
2006	   1,2	   1	   1	   1	   1	   1	  
UK17	   H072360520	   ERS018358	   Manchester	   01-­‐Jun-­‐07	   1,3	   3	   1	   2	   1	   2	  
UK18	   H104520431	   ERS018359	   	  Stevenage	   02-­‐Nov-­‐10	   1,3	   3	   1	   4	   1	   1	  
UK20	   H094780268	   ERS018360	   	  Liverpool	   15-­‐Nov-­‐09	   1,3	   3	   1	   2	   1	   3	  
UK21	   H100760146	   ERS018361	   	  Manchester	  
February	  
2010	   1,2	   3	   1	   2	   1	   1	  
UK22	   H100980734	   ERS018362	   Slough	   March	  2010	   1,2	   1	   1	   1	   1	   1	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UK23	   H102820210	   ERS018363	   Peterborough	   28-­‐Jun-­‐10	   1,3	   3	   1	   2	   1	   1	  
UK24	   H104460387	   ERS018364	   Kent	   25-­‐Oct-­‐10	   1,3	   3	   1	   	  	   1	   1	  
UK25	   H080420101	   ERS176852	   Birmingham	   09-­‐Jan-­‐08	   1,3	   3	   1	   2	   1	   1	  
UK26	   H083360066	   ERS176853	   Manchester	   28-­‐Jul-­‐08	   1,3	   3	   1	   2	   1	   1	  
UK27	   H085180127	   ERS176854	   	  Leeds	   22-­‐Nov-­‐08	   	  1,3	   3	   1	   2	   1	   2	  
UK28	   H090760338	   ERS176855	   Cambridge	   29-­‐Jan-­‐09	   	  1,3	   3	   1	   2	   1	   2	  
UK29	   H094840822	   ERS176856	   Hounslow	   21-­‐Nov-­‐09	   	  1,2	   3	   1	   2	   1	   1	  
UK30	   H111420251	   ERS176857	   Derby	   28-­‐Mar-­‐11	   	  1,3	   3	   1	   2	   1	   1	  
UK31	   H111920356	   ERS176858	   Scunthorpe	   27-­‐Apr-­‐11	   	  1,2	   1	   1	   3	   1	   1	  
UK32	   H110620329	   ERS176859	   Southport	   31-­‐Jan-­‐11	   	  1,3	   3	   1	   2	   1	   2	  
UK33	   H111340193	   ERS176860	   Leicester	   18-­‐Mar-­‐11	   	  1,3	   3	   1	   2	   1	   2	  
UK34	   H113820371	   ERS176861	   Scarborough	   19-­‐Sep-­‐11	   	  1,2	   3	   1	   2	   1	   1	  
UK35	   H121080103	   ERS176862	   Kings	  Lynn	   26-­‐Feb-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK36	   H121120872	   ERS176863	   Slough	   06-­‐Mar-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK37	   H121120873	   ERS176864	   Slough	   06-­‐Mar-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK38	   H121320680	   ERS176865	   Slough	   05-­‐Mar-­‐12	   	  1,3	   3	   1	   2	   1	   2	  
UK39	   H121340485	   ERS176866	   Southampton	   14-­‐Mar-­‐12	   	  1,3	   3	   1	   2	   1	   2	  
UK40	   H121340484	   ERS176867	   Leeds	   18-­‐Mar-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK41	   H123080639	   ERS176868	   Halifax	   20-­‐Jul-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK42	   H123120553	   ERS176869	   	  Ashford	   11-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK43	   H123140609	   ERS176870	   Norwich	   20-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK44	   H123180882	   ERS176871	   Truro	   21-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK45	   H123180902	   ERS176872	   	  Truro	   19-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK46	   H123040595	   ERS176873	   Cardiff	   17-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   1	  
UK47	   H123040596	   ERS176874	   Bristol	   11-­‐Jul-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK48	   H123040597	   ERS176875	   Kingston	   11-­‐Jul-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK49	   H123040834	   ERS227750	   Belfast	   17-­‐Jul-­‐12	   	  1,3	   3	   1	   2	   1	   2	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UK50	   H123060621	   ERS227751	   Kettering	   13-­‐Jul-­‐12	   	  1,2	   3	   1	   	  	   1	   1	  
UK51	   H115020415	   ERS227752	   	  Derby	   01-­‐Dec-­‐11	   1,3	   1	   1	   1	   1	   1	  
UK52	   H115060354	   ERS227753	   Plymouth	   06-­‐Dec-­‐11	   	  1,2	   3	   1	   2	   1	   1	  
UK53	   H120180199	   ERS227754	   Torbay	   22-­‐Dec-­‐11	   1,3	   3	   1	   2	   1	   2	  
UK54	   H120260403	   ERS227755	   Exeter	   30-­‐Dec-­‐11	   1,3	   3	   1	   2	   1	   1	  
UK55	   H120300223	   ERS227756	   	  Belfast	   05-­‐Jan-­‐12	   	  1,2	   3	   1	   	  	   1	   1	  
UK56	   H120420417	   ERS227757	   St.	  Helier	   13-­‐Jan-­‐12	   	  1,2	   1	   1	   1	   1	   1	  
UK57	   H120520440	   ERS227758	   	  Newcastle-­‐Upon-­‐Tyne	   17-­‐Jan-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK58	   H120620487	   ERS227759	   Exeter	   28-­‐Jan-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK59	   H120700084	   ERS227760	   Poole	   02-­‐Feb-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK60	   H120860175	   ERS227761	   Galway	   21-­‐Feb-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK61	   H121000369	   ERS227762	   Dorchester	   27-­‐Feb-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK62	   H121080104	   ERS227763	   Birmingham	   02-­‐Mar-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK63	   H121120583	   ERS227764	   Ipswich	   02-­‐Mar-­‐12	   1,3	   3	   1	   	  	   1	   1	  
UK64	   H121120585	   ERS227765	   Norwich	   27-­‐Feb-­‐12	   1,3	   3	   1	   	  	   1	   1	  
UK65	   H121360522	   ERS227766	   Kettering	   19-­‐Mar-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK66	   H121440482	   ERS227767	   Exeter	   02-­‐Apr-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK67	   H121460713	   ERS227768	   Stockport	   30-­‐Mar-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK68	   H121560437	   ERS227769	   Frimley	   03-­‐Apr-­‐12	   	  1,2,3	   3	   1	   2	   1	   1	  
UK69	   H121560438	   ERS227770	   Worthing	   03-­‐Apr-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK70	   H121940701	   ERS227771	   Burton-­‐On-­‐Trent	   01-­‐May-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK71	   H121940704	   ERS227772	   Cardiff	   20-­‐Apr-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK72	   H122040731	   ERS227773	   Dorchester	   10-­‐May-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK73	   H122120592	   ERS227774	   Nottingham	   10-­‐May-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK74	   H122220497	   ERS227775	   Southport	   29-­‐May-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK75	   H122380455	   ERS227776	   Leicester	   01-­‐Jun-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK76	   H122560437	   ERS227777	   Bristol	   06-­‐Jun-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
	   90	  
UK77	   H122580435	   ERS227778	   North	  Shields	   21-­‐Jun-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK78	   H122700116	   ERS227779	   Bristol	   14-­‐Jun-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK79	   H122860244	   ERS227780	   	  Stoke-­‐On-­‐Trent	   02-­‐Jul-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK80	   H122920208	   ERS227781	   Ipswich	   06-­‐Jul-­‐12	   1,3	   3	   1	   	  	   1	   2	  
UK81	   H122980531	   ERS227782	   	  Boston	   09-­‐Jul-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK82	   H123000341	   ERS227783	   Newcastle-­‐Upon-­‐Tyne	   11-­‐Jul-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK83	   H123300481	   ERS227784	   Nottingham	   01-­‐Aug-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK84	   H123380565	   ERS227785	   	  Ipswich	   06-­‐Aug-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK85	   H123600404	   ERS227786	   York	   23-­‐Aug-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK86	   H123620609	   ERS227787	   Scunthorpe	   03-­‐Sep-­‐12	   	  1,2	   3	   1	   	  	   1	   1	  
UK87	   H123760736	   ERS227788	   Birmingham	   28-­‐Aug-­‐12	   1,3	   3	   1	   	  	   1	   1	  
UK88	   H123800680	   ERS227789	   Sheffield	   05-­‐Sep-­‐12	   1,3	   3	   1	   3	   1	   2	  
UK89	   H123880654	   ERS227790	   Oldham	   12-­‐Sep-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK90	   H123940665	   ERS227791	   Crawley	   13-­‐Sep-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK91	   H124140572	   ERS227792	   Dorchester	   01-­‐Oct-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK92	   H124320838	   ERS227793	   Bristol	   03-­‐Oct-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK93	   H124620975	   ERS227794	   Newcastle-­‐Upon-­‐Tyne	   04-­‐Nov-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK94	   H124740775	   ERS227795	   	  Durham	   12-­‐Nov-­‐12	   	  1,2	   3	   1	   2	   1	   1	  
UK95	   H124960781	   ERS227796	   	  Leeds	   28-­‐Nov-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK96	   H125040728	   ERS227797	   Gloucester	   30-­‐Nov-­‐12	   	  1,2	   	  	   	  	   	  	   	  	   	  	  
UK97	   H125080782	   ERS227798	   Halifax	   03-­‐Dec-­‐12	   1,3	   3	   1	   2	   1	   1	  
UK98	   H125180676	   ERS227799	   	  Truro	   10-­‐Dec-­‐12	   1,3	   3	   1	   2	   1	   2	  
UK99	   H125180677	   ERS227800	   Bristol	   12-­‐Dec-­‐12	   	  1,2	   3	   1	   2	   1	   1	  


















I	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK01	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK02	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK03	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK04	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK05	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK06	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK08	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK09	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK10	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK11	   NK	   NK	   NK   NK NK NK NK NK NK NK 
UK14	   20	  m	   M	   YES NK NK NK NK NK NK NK NK 
UK15	   1	  y	  8	  m	   M	   NK   NK NK NK NK NK NK NK 
UK16	   6	  w	   M	   NO   January 2006 Yes YES NO YES NO YES 
UK17	   1	  m	   M	   NO   NK NK NK NK NK NK YES 
UK18	   1	  m	   M	   YES 1 28/10/10 NK YES NO NO NO YES 
UK20	   2	  m	   F	   YES 3 07/12/09 YES NO NO NO NO NO 
UK21	   1	  m	   F	   NK   NK NK NK NK NK NK NK 
UK22	   1	  m	   M	   NO   21/02/10 YES YES NO YES NO YES 
	   92	  
UK23	   3	  w	   F	   NO   21/06/10 YES YES NO NK NO YES 
UK24	   5	  d	   F	   No   00/01/1900 NK NK NK NK NK NK 
UK25	   3	  m	   F	   YES 1 05/01/08 YES NO NO NO NO YES 
UK26	   2	  m	   U	   NO   15/07/08 YES NO NO NO NO NK 
UK27	   2	  m	   M	   NO   18/11/08 NO NO NO NO NO YES 
UK28	   3	  m	   F	   YES 2 01/01/09 YES NO NO NO NO NO 
UK29	   2	  m	   M	   NO   MidNovember 2009 YES NO NO NO YES YES 
UK30	   14	  y	   F	   YES 3 14/03/11 YES NO NO NO NO NO 
UK31	   52	  y	   F	   NO   07/04/11 YES NO NO NO NO NO 
UK32	   1m	   F	   NO   20/01/11 YES NO NO NK NO YES 
UK33	   1m	   M	   NK   08/03/11 NK NO NO YES YES YES 
UK34	   3m	   M	   NO   30/08/11 YES NO NO NO NO YES 
UK35	   1m	   M	   NO   NK NO YES NK YES YES YES 
UK36	   15y	   M	   YES 3 01/03/12 YES NO NO NO NO NO 
UK37	   13y	   M	   YES 4 04/03/12 YES NO NO NO NO NO 
UK38	   14y	   M	   YES 3 28/02/12 YES NO NO NO NO NO 
UK39	   16y	   M	   YES 3 09/03/12 YES NO NO NO NO NO 
UK40	   2m	   M	   NO   14/03/12 NK NK NK NK YES YES 
UK41	   1m	   M	   NK   NK NK NK NK NK NK YES 
UK42	   2m	   F	   NO   28/06/12 YES NK NO NO NO YES 
UK43	   1m	   M	   NO   10/07/12 YES NK NK NO NK YES 
UK44	   8m	   M	   YES 1 11/07/12 NK NK NK NK NK YES 
UK45	   8m	   F	   NK   11/07/12 NO NK NK NK NK YES 
UK46	   1m	   M	   NO   14/07/12 YES YES NK NK NO YES 
UK47	   2m	   F	   NO   02/07/12 NO NO NO YES NO YES 
UK48	   1m	   F	   NO   16/06/12 YES NO NO NK NO YES 
UK49	   2m	   M	   NK   NK NK NK NK NK NK YES 
	   93	  
UK50	   1m	   M	   NO   02/07/12 NO YES NO NO NO YES 
UK51	   8m	   M	   NO   22/11/11 NO NO NO NO NO YES 
UK52	   1m	   M	   NO   23/11/11 YES YES NO NK NO YES 
UK53	   11	  y	  6m	   M	   NO   NK YES NO NO NO NO NO 
UK54	   16	  y	  2m	   F	   YES 3 NK NK NK NK NK NK YES 
UK55	   2	  m	   M	   NK   NK NK NK NK NK NK YES 
UK56	   22	  y	  3	  m	   F	   NK   NK NK NK NK NK NK NK 
UK57	   3m	   F	   YES 2 17/01/12 YES NK NK NK NK YES 
UK58	   1m	   M	   NO   16/01/12 NK NO NO NO NO YES 
UK59	   1m	   M	   NO   23/01/12 NK NO NO NO NO YES 
UK60	   4y	  4m	   F	   NK   NK NK NK NK NK NK YES 
UK61	   12y	  1m	   M	   YES 4 ca.January 2012 YES NO NO NO NO YES 
UK62	   1m	   M	   NO   28/02/12 YES NO NO NO NO YES 
UK63	   64y	  6m	   M	   NK   22/02/12 YES NO NO NO NO NO 
UK64	   10m	   M	   NK   06/02/12 YES NK NK NK NK YES 
UK65	   12y	  2m	   F	   NO   07/03/12 YES NO NO NO NO NO 
UK66	   1m	   F	   NO   21/03/12 YES NO NO NO NO YES 
UK67	   3m	   M	   NO   14/03/12 YES NO NO YES NO YES 
UK68	   2m	   F	   NO   26/03/12 YES NO NO NO NO YES 
UK69	   14y	  10m	   F	   YES 3 14/02/12 YES NO NO NO NO NO 
UK70	   2m	   M	   YES 1 15/04/12 YES NK NO NO NO YES 
UK71	   2m	   F	   NO   01/04/12 YES NK NK NK NO YES 
UK72	   27y	  3m	   M	   YES   08/05/12 YES NO NO NO NO NO 
UK73	   1	  m	   M	   NK   NK NK NK NK NK NK YES 
UK74	   4m	   F	   YES 2 08/05/12 YES NK NK NO NO YES 
UK75	   3m	   F	   NO   28/04/12 YES NO NO NO NO YES 
UK76	   59y	  2m	   F	   NK   01/05/12 YES NO NO YES NO NO 
	   94	  
UK77	   1y	  5m	   F	   YES 3 15/05/12 YES NO NO NO NO NO 
UK78	   28y	  9m	   F	   NK   01/06/12 YES NO NO NO NO NO 
UK79	   4m	   F	   NO   02/06/12 YES NK NO NO NO YES 
UK80	   55y	  10m	   M	   NO   05/07/12 YES NO NO NO NO NO 
UK81	   2y	   M	   NO   29/06/12 YES NO NO NO NO NO 
UK82	   29y	  11m	   M	   YES 3 02/07/12 YES NK NK NK NK NO 
UK83	   10m	   F	   NO   23/07/12 NO NO NO NO NO NO 
UK84	   48	  y	  7	  m	   F	   YES 3 Mid-July 2012 YES NO NO NO NO NO 
UK85	   15	  y	  3	  m	   M	   YES 3 01/08/12 YES NO NO NO NO YES 
UK86	   6	  m	   M	   NO   24/08/12 YES NO NO NO NO NO 
UK87	   1	  y	  11	  m	   F	   YES 3 07/08/12 NO NO NO NO NO YES 
UK88	   50	  y	  10	  m	   M	   NO   28/08/12 YES NO NO NO NO YES 
UK89	   8	  y	  3	  m	   M	   YES 3 07/09/12 YES NO NO NO NO NO 
UK90	   5	  y	  2m	   F	   NO   06/09/12 NO NO NO NO NO NO 
UK91	   2	  m	   F	   NO   24/09/12 NO YES NO NO NO YES 
UK92	   70	  y	  11	  m	   F	   NK   01/10/12 YES NO NO NO NO NO 
UK93	   3	  w	   M	   NO   NK NK NK NK NK NO YES 
UK94	   45	  y	  10	  m	   F	   NK   30/10/12 YES NO NO NO NO NO 
UK95	   81	  y	  7	  m	   F	   NO   19/11/12 YES NO NO NO NO NO 
UK96	   28	  y	  7m	   F	   YES 3 NK YES NO NO NO NO NO 
UK97	   1	  m	   M	   NO   03/12/12 YES NK NK NK NO YES 
UK98	   46	  y	  5m	   F	   NK   03/12/12 YES NO NO NO NO NO 
UK99	   24	  y	  4m	   M	   YES 3 05/12/12 YES NO NO NO NO NO 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M A J O R A R T I C L E
Genomic Analysis of Isolates From the United
Kingdom 2012 Pertussis Outbreak Reveals That
Vaccine Antigen Genes Are Unusually Fast
Evolving
Katie L. Sealey,1,2 Simon R. Harris,3 Norman K. Fry,2 Laurence D. Hurst,1 Andrew R. Gorringe,4 Julian Parkhill,3 and
Andrew Preston1
1Department of Biology and Biochemistry, University of Bath, 2Public Health England, Respiratory and Vaccine Preventable Bacteria Reference Unit,
London, 3Wellcome Trust Sanger Institute, Hinxton, and 4Public Health England, Porton Down, Salisbury, United Kingdom
A major outbreak of whooping cough, or pertussis, occurred in 2012 in the United Kingdom (UK), with nearly
10 000 laboratory-conﬁrmed cases and 14 infant deaths attributed to pertussis. A worldwide resurgence of per-
tussis has been linked to switch to the use of acellular pertussis vaccines and the evolution of Bordetella pertussis
away from vaccine-mediated immunity. We have conducted genomic analyses of multiple strains from the UK
outbreak.We show that the UK outbreak was polyclonal in nature, caused by multiple distinct but closely related
strains. Importantly, we demonstrate that acellular vaccine antigen–encoding genes are evolving at higher rates than
other surface protein–encoding genes. This was true even prior to the introduction of pertussis vaccines but has
become more pronounced since the introduction of the current acellular vaccines. The fast evolution of vaccine an-
tigen–encoding genes has serious consequences for the ability of current vaccines to continue to control pertussis.
Keywords. pertussis; genomics; evolution; vaccine.
Whooping cough, or pertussis, is caused primarily by
the bacterium Bordetella pertussis. In England and
Wales, 9711 laboratory-conﬁrmed cases were recorded
in 2012, leading to 14 deaths of infants <3 months of
age. This was much greater than the previous recent
peak year in 2008, in which 902 cases were reported, de-
spite levels of vaccine coverage and diagnostic methods
not changing during this period [1, 2]. Similar outbreaks
have been reported across the globe [3], contributing to
the consensus that pertussis is a resurgent disease that
might be no longer effectively controlled by current vac-
cination programs.
Resurgence has been linked to increased surveillance,
better diagnostic techniques, incomplete vaccination of
populations, and, primarily, the switch from whole-cell
pertussis vaccines (WCVs) to acellular pertussis vac-
cines (ACVs), which contains 1–5 puriﬁed B. pertussis
protein antigens: pertussis toxin (Ptx), ﬁlamentous
hemagglutinin (FHA), pertactin (Prn), and ﬁmbrial
type 2 (Fim2) and Fim3. In the United Kingdom (UK),
a 5-antigen ACV has been used. ACV-induced immu-
nity appears to be shorter lived than that induced by
WCVs, possibly resulting in an expanded pool of carri-
ers, particularly adolescents, and decreased herd immu-
nity [4, 5]. In addition, studies using an infant baboon
model revealed that, while ACVs protect the individual
from disease symptoms, they are less able to prevent
colonization of and transmission from the vaccinee,
compared with WCVs. Increased transmission of
B. pertussis in populations using ACVs, compared
with those using WCVs, is proposed to contribute to
the resurgence [6]. Finally, it has been proposed that
vaccine-induced escape mutants are arising, because
ACV-induced immunity is focused on just a few antigens
and because changes in these antigens might result in
strains that are less well recognized by this immunity [7].
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The frequency of different alleles of vaccine antigen–encoding
genes among strains has changed over time [8–11]. The most
common allelic proﬁle among currently circulating strains
(ptxA1-ptxP3, prn2, ﬁm3-2, and ﬁm2-1) is different from that
of strains used for vaccine manufacture [12, 13], and isolates
that do not express Prn are increasingly common [14–16].
PtxP refers to alleles of the ptx promoter. PtxP3 is now domi-
nant worldwide [17], and some studies suggest that ptxP3
strains may have increased virulence, compared with ptxP1
strains [18].
The study of genetic changes in B. pertussis over time was
hindered by the high levels of homogeneity among B. pertussis
and the lack of ﬁne-resolution tools. Recently, the genome se-
quences of a large panel of B. pertussis strains collected from
around the world and across many decades were generated
and analyzed [19]. This provided detailed information about
the population structure and evolution of B. pertussis, revealing
signiﬁcant genetic changes among strains over the last 50 years.
A lack of geographical clustering of strains suggested rapid
strain ﬂow between countries. However, this panel of strains
did not contain isolates collected more recently than 2008, ex-
cept for 3 isolates from the Netherlands, which were collected in
2009 and 2010. In addition, the panel did not include a substan-
tial number of isolates from a speciﬁc outbreak, leaving the
genetic make-up of isolates involved in such events largely
unknown. Here, we analyze a large panel of UK strains, with
a focus on strains from the recent UK outbreak, to understand
the clonal structure of the outbreak and determine whether
there is evidence for vaccine-mediated immunity driving the
evolution of these strains.
METHODS
Accession Numbers
Genome sequence data has been deposited in the European
Nucleotide Archive (http://www.ebi.ac.uk/ena/; Supplementary
Table 1).
B. pertussis Strains
One hundred B. pertussis isolates were obtained from the
National Reference Laboratory, Respiratory and Vaccine Pre-
ventable Bacteria Reference Unit, at Public Health England
(Supplementary Table 1). Five strains were collected between
1920 and 1956 (hereafter referred to as the “prevaccine era”),
6 strains collected between 1957 and 2000 (hereafter, the
“WCV era”), and 89 strains were collected between 2000 and
2012 (hereafter, the “ACV era”). Serotyping was performed
using sera speciﬁc for antigens 1, 2, and 3 (89/596, 89/598,
and 89/600, respectively; National Institute for Biological Stan-
dards and Controls, Potters Bar, UK) as previously described
[12]. Tohama I (accession number: BX470248), a strain isolated
in Japan in 1954, is the most widely studied strain, provides the
reference genome sequence of B. pertussis [20], and is one of the
strains used to produce ACVs used in the UK. B. pertussis iso-
lates were grown on charcoal agar for 72 hours at 37°C.
DNA Preparation
Genomic DNA extraction was performed using the Qiagen
DNA prep kit according to the manufacturer’s instructions.
DNA Sequencing and Single-Nucleotide Polymorphism (SNP)
Identiﬁcation
Twenty four isolates were sequenced previously [19]. For the re-
mainder, multiplex libraries, with fragment sizes between 300 bp
and 500 bp, were prepared as previously described [21], with
modiﬁcations [22]. Reads for each isolate were aligned to
the Tohama I reference genome, using SMALT, version 0.7.4
(http://www.sanger.ac.uk/resources/software/smalt/). Base calls
were made as previously described [21], using a combination
of samtools, mpileup, and bcftools [23], allowing SNPs, and
small insertions and deletions relative to Tohama I to be iden-
tiﬁed. Five strains produced poor-quality sequence and were ex-
cluded from the analysis, resulting in 95 strains being taken
forward for analysis.
Phylogenetic Analysis
Maximum likelihood phylogenetic analysis was performed on
variable sites from across the whole genomes, using RAxML
under a general time-reversible evolutionary model and a Γ cor-
rection for among site rate heterogeneity [24]. One hundred
random bootstrap replicates were run to provide support for re-
lationships identiﬁed in the tree.
Analysis of SNP Densities
SNPs were reconstructed on to the phylogenetic tree using par-
simony. SNP densities (deﬁned as the number of SNPs per bp)
within vaccine antigen–encoding genes (9 genes: fhaB, prn,
ﬁm2, ﬁm3, and ptxA–E) or functional cell surface protein–
encoding genes (591 genes, as categorized previously [20])
were calculated by counting the number of SNPs per bp of
each gene. The difference between the mean per-gene SNP
densities of vaccine antigen–encoding genes and cell surface
protein–encoding genes was calculated. The signiﬁcance of
this difference was calculated using a nonparametric Monte
Carlo simulation. In our randomizations of all the data, preserv-
ing relative sample sizes, it was recorded how often a difference
as large, or greater than the difference above, was observed, by
repeated randomly resampling 2 samples of the same size as
above. Under this protocol, if n is the number of observations
that have greater than or equal to the observed difference in
SNP density and m is the number of simulations (in this case,
10 000), then P = [n + 1]/[m + 1] is the unbiased estimator of
the type I error rate.
We performed a similar procedure to compare SNP densities
in vaccine antigen–encoding genes between eras. To account for
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differences in SNP densities between strains from the different
eras, the SNP densities of the vaccine antigen–encoding genes
were normalized with respect to the SNP densities of all the
genes considered (vaccine antigen–encoding and surface pro-
tein–encoding genes). A nonparametric Monte Carlo simula-
tion compared the normalized SNP densities in the ACV
antigen genes in ACV-era strains with those for pre–ACV-era
strains, with P determined as described above.
Allele Typing
The different alleles of prn, ptxA, ptxP, ﬁm3, and ﬁm2 genes
have been previously described [11] and were used to identify
allele types from DNA sequences.
Analysis of prn From UK50
The prn locus was ampliﬁed from UK50 by polymerase chain
reaction (PCR) analysis, using primers 5′-CCGCTGATTCGC
CACAAG-3′ and 5′-GTGCGGTACTTGCCCTTG-3′. PCR
products were cloned using the Gateway system (Invitrogen,
Paisley, UK) and sequenced by Euroﬁns Genomics (Ebersberg,
Germany), using standard M13 forward and reverse primers
and internal primers 5′-GCGCACGCCTGTCCAAAG-3′ and
5′-TAGCGAGCCAGCACGTAG-3′.
Analysis of Differences in DNA Content Among Strains
To detect gene loss from strains, compared to the DNA content
of Tohama I, coverage plots generated using the paired-end
reads mapped to this reference genome were used to create a
heat map. DNA sequence contigs that did not map to Tohama
I were analyzed using Blastn and Blastx (http://blast.ncbi.nlm.
nih.gov/Blast.cgi).
RESULTS
Phylogeny of UK Strains From 1920 to 2012
Phylogenetic analysis based on SNPs across the whole-genome
sequences was performed to understand the evolutionary rela-
tionships between the UK strains analyzed (Figure 1 and Sup-
plementary Table 1). Strains isolated during 1920–1982 form a
cluster and are generally separated from strains isolated during
2008–2012. The most distinct clustering separates strains carry-
ing the ptxP1 allele from those carrying the ptxP3 allele, which,
as found elsewhere, is the predominant ptxP type among recent
strains. This phylogenetic analysis was extended to place the UK
strains in the global phylogenetic tree described elsewhere (Fig-
ure 2) [19]. This reveals that the UK ptxP3 strains separate into
2 clusters distinguished by the presence of the ﬁm3-2 allele. The
UK outbreak strains largely cluster with strains isolated mainly
during the early 2000s from a variety of geographical areas, in-
cluding North America, Europe, and Australia.
Vaccine Antigen Allele Proﬁles
Previously, ptxP3-ptxA1-prn2-ﬁm3-2 was deﬁned as the domi-
nant allele type circulating in the UK and other countries [17].
Typing of alleles among the outbreak strains reveal no recent
change in this proﬁle (Table 1). Numerous isolates deﬁcient
for the production of Prn have been reported in other countries,
and a number of different mutations in prn responsible for this
phenotype identiﬁed [14–16]. It has been suggested that loss of
Prn expression has been selected by vaccine-mediated immuni-
ty pressure. Interestingly, just a single UK strain, UK50, was
mutated for prn. This was identiﬁed by a lack of sequence
reads mapping to a region of prn. The prn locus was ampliﬁed
Figure 1. Phylogenetic tree depicting the evolutionary relationships among the United Kingdom (UK) Bordetella pertussis isolates studied here. Max-
imum likelihood phylogenetic analysis was performed on variable sites from across the whole genomes, using RAxML. Strains are shaded according to their
year of isolation and ptxP type.
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by PCR from this strain, and the resulting product was se-
quenced using Sanger sequencing. This identiﬁed that a recom-
bination event between 2 copies of IS1663 resulted in a deletion/
insertion mutation in which the 5′ 1326-bp region of the prn
coding sequence was deleted. Aberrant mapping was not ob-
served for any other UK strain. In other countries, a common
prn mutation arose from insertion of IS481 into prn. We iden-
tiﬁed paired-end reads in which one read mapped within IS481
but the other did not and, thus, derives from the region ﬂanking
IS481. Mapping these reads to the reference genome identiﬁed
the position of the copies of IS481 within each query strain. No
IS481 insertions into prn were identiﬁed among UK strains. It is
not clear why so few Prn-deﬁcient strains, compared with other
countries experiencing pertussis outbreaks, have been identiﬁed
in the UK.
SNPs Speciﬁc to ptxP3 Strains
ptxP3 strains are the predominate type in current circulation
and appear to have infection-associated biologic characteristics
that differ from those of ptxP1 strains. The ptxP3 SNP appears
to be both a direct cause and a marker for other genetic
variations that contribute to this difference [18]. To investigate
the genetic traits of UK ptxP3 strains, SNPs speciﬁc to this lin-
eage were identiﬁed. In total, 22 such SNPs were identiﬁed
(Table 2). Ten were intergenic, of which 7 were in the direct re-
peat region of IS elements, which are present in multiple copies
in the B. pertussis genome. It is not clear whether these partic-
ular IS elements are functional. Twelve SNPs were in coding re-
gions. Of those, 7 were nonsynonymous mutations (NSMs) and
5 were synonymous mutations (SMs). The 7 NSMs were in
genes within the functional categories “transport/binding pro-
teins,” “conserved hypothetical,” “pathogenicity,” “unknown,”
and “regulation” or as “pseudogenes” as previously described
[20]. All of these SNPs were also identiﬁed among the global
panel of B. pertussis strains [19]. However, of the 22 SNPs iden-
tiﬁed here as being ptxP3 speciﬁc, only 10 were identiﬁed as
being ptxP3-type speciﬁc in the previous study (Table 2); the
other 12 SNPs were also identiﬁed among non-ptxP3 strains
globally.
Figure 2. Phylogenetic relationships of United Kingdom (UK) strains
within a global context. The UK isolates analyzed here are indicated.
Table 1. Frequency of Vaccine Antigen–Encoding Gene Alleles












1 100 100 6
3 0 0 94
ptxA
1 20 100 100
2 80 0 0
Prna
1 100 84 5
2 0 0 91
3 0 16 3
4 0 0 1
Fim2-
1 100 100 100
Fim3-
1 100 100 70
2 0 0 29
3 0 0 1
Serotype
1b 20 0 0
1, 2 40 50 37
1, 3 20 17 63
1, 2, 3 20 33 0
Data are percentage of strains tested.
Abbreviations: ACV, acellular pertussis vaccine; WCV, whole-cell pertussis
vaccine.
a Prn allele type was determined for just 76 ACV era strains, owing to poor
mapping of reads in this region in 8 strains.
b Serotype was not determined for one ACV era strain. Thus, frequencies are
based on 83, not 84, strains in this era.
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SNP Rates Are High in Vaccine Antigen–Encoding Genes
Previously, it was identiﬁed that genes encoding functional cell
surface proteins had higher SNP densities than the B. pertussis
chromosomal average [19]. However, ACV-mediated immunity
is exerting selective pressure primarily on the proteins used in
these vaccines and might be driving their evolution. To explore
this, the SNP density for the 9 ACV antigen-encoding genes
(Ptx comprises 5 different proteins) and for the other 591
genes composing the cell surface protein category was calculat-
ed for all strains within each vaccine era and compared. Second,
we investigated whether the SNP rate in ACV antigen–encoding
genes had increased since the introduction of ACVs.
The difference in mean SNP density across genes within the 2
samples (calculated as the mean SNP density in vaccine anti-
gen–encoding genes minus the mean SNP density in cell surface
protein–encoding genes) was calculated. A nonparametric
Monte Carlo simulation was used to assess the signiﬁcance of
this difference by determining how often a difference as large
or larger than this was derived by randomly resampling, from
the pool of vaccine antigen–encoding and cell surface pro-
tein–encoding genes, 2 samples of the same size as the 2
samples described above. This revealed that, in each era, vaccine
antigen–encoding genes had signiﬁcantly higher SNP densities
than other cell surface protein–encoding genes (P < .05;
Table 3), with the difference being greatest among ACV-era
strains. This suggests that the vaccine antigen–encoding genes
are faster evolving than other surface protein–encoding genes
and that they were also faster evolving even before the introduc-
tion of widespread vaccination.
To compare SNP densities in vaccine antigen–encoding
genes between eras, SNP densities within each era were normal-
ized by dividing by the mean SNP rate across all of the genes
concerned (ie, those encoding ACV antigens and cell surface
proteins). In comparison to the prior analysis, this has less
power, owing to the much smaller sample of ACV antigen–
encoding genes, compared with the total number of cell surface
protein–encoding genes. Although the normalized SNP density
in ACV-era strains was greater than in pre–ACV era strains, the
difference was not statistically signiﬁcant (P = .160). However,
the number of pre-ACV strains in this analysis was small.
Thus, the same analyses were repeated, using SNP data from
the global collection of strains for which the year of isolation




36 857 INT A→G Yes 93 bp upstream of BP0032 (encoding a putative transport protein), 156 bp upstream of BP0033
(encoding GlyQ-glycyl-tRNA synthetase α chain)
617 083 INT T→G No Within the 5′ repeat region of IS481 (BP0611), 31 bp upstream of transposase start codon.
617 084 INT C→T No Within the 5′ repeat region of IS481 (BP0611), 32 bp upstream of transposase start codon.
1 077 844 INT C→T No Within the 5′ repeat region of IS1663 (BP1035), 139 bp upstream of transposase start codon.
1 170 424 INT A→G No Within the 5′ repeat region of IS481 (BP1114), 31 bp upstream of transposase start codon.
1 222 400 INT A→C No Within the 5′ repeat region of IS481 (BP1157), 31 bp upstream of transposase start codon.
1 635 654 INT T→G No Within the 5′ repeat region of IS481 (BP1557), 31 bp upstream of transposase start codon.
2 259 917 INT G→C No Within the 5′ repeat region of IS481 (BP2135), 98 bp upstream of transposase start codon.
3 263 622 INT A→C Yes 193 bp away from BP3062, putative integral membrane transport protein.
3 988 168 INT G→A Yes 89 nucleotides away from the start codon of ptxA, ptxP3allele
196 307 NSM T→C Yes BP0194, putative transport protein
299 559 NSM C→T Yes BP0292, pseudogene, conserved hypothetical protein
1 331 840 NSM G→A Yes Pseudogene, BP1261, hypothetical protein
1 547 488 NSM A→G No BP1471, conserved hypothetical protein
2 374 322 NSM T→C Yes BP2249, BscI, type III secretion apparatus protein
2 651 008 NSM G→A Yes BP2502, Hypothetical protein
3 134 458 NSM G→C No BP2946, probable transcriptional regulator
185 405 SM G→A No BP0184, putative periplasmic protein
518 837 SM T→C No BP0507, putative membrane protein
694 521 SM A→G Yes BP0678, Putative peptide chain release factor
3 840 411 SM G→A Yes BP3630, RpsH, 30S ribosomal protein
3 991 376 SM C→T No BP3787, PtxC, Pertussis toxin subunit protein
Abbreviations: INT, SNP is in an intergenic region; NSM, nonsynonymous mutation; SM, synonymous mutation.
a Tohama I reference genome coordinates (accession no. BX470248).
b “Yes” denotes that the SNP was also defined as ptxP3 specific in study of the global Bordetella pertussis population [1], whereas “No” denotes that the SNP was
not defined as such in the study.
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was known [19] and incorporating the UK strains sequenced
here (Table 3). Again, a signiﬁcantly greater SNP frequency
was found in ACV antigen–encoding genes, compared with
other cell surface protein–encoding genes, in all 3 eras. This
time, there was also a signiﬁcantly higher SNP frequency in
ACV antigen–encoding genes among ACV era strains, com-
pared with pre–ACV era strains (P = .0177), suggesting that
the relative SNP density in ACV antigen–encoding genes has in-
creased since the introduction of ACVs. These results suggest
that ACV antigen–encoding genes are intrinsically fast evolving
and provide some support for the hypothesis that they have
evolved even faster since the introduction of ACVs.
The more rapid evolution in the ACV antigen–encoding
genes could be due to either a higher underlying mutation
rate or different selection at the protein level. The different
selection could be positive selection or weaker purifying selec-
tion. To distinguish between these 2 possibilities, SNPs were
split into SMs and NSMs. High NSM but not SM rates would
suggest altered protein-level selection. A higher rate of synony-
mous evolution (with possibly a weak nonsynonymous effect)
would suggest higher mutation rates. Interpretation here is dif-
ﬁcult, owing to well-described but incompletely understood
correlation between SM and NSM rates.
Among WCV- and ACV-era global strains but not prevac-
cine era strains, the SM frequency was signiﬁcantly higher in
ACV antigen–encoding genes, compared with other cell surface
protein–encoding genes (Table 4). When comparing ACV-era
strains to pre-ACV era strains, the SM frequency in ACV anti-
gen genes was signiﬁcantly higher (P = .004). NSMs also
occurred at a signiﬁcantly greater frequency in ACV antigen–
encoding genes, compared with other cell surface protein–
encoding genes (Table 4). The magnitude of this effect is greater
than that seen for SMs, suggesting the higher evolutionary rate
of ACV antigen–encoding genes, compared with cell surface
protein–encoding genes, is largely owing to protein-level selec-
tion on the antigens. Evidence for a strong recent increase is less
clear-cut. When comparing strains from the ACV-era to pre-
ACV era strains, the NSM frequency in ACV antigen genes
was on the edge of signiﬁcance (P = .051). Overall, our results
provide support for the hypothesis that the genes encoding an-
tigens chosen for ACVs are intrinsically fast evolving, in part
owing to selection pressure on their antigenic products. We can-
not discount the possibility that, in the ACV era, there has been
an increase in the mutation rate (see “Discussion” section).
Regions of Difference
Deletions have been a major feature of B. pertussis evolution
and appear to be ongoing [20, 25]. Compared with the Tohama
I reference genome, most of the major deletions observed
among the strains analyzed here had been identiﬁed previously
[25]. Numerous small deletions were found in only a few iso-
lates or just 1 isolate, suggesting that deletion of DNA is com-
mon among B. pertussis strains. Interestingly, some deletions
appeared to be speciﬁc to the UK ptxP3 strains, but no deletions
speciﬁc to outbreak isolates were detected (Supplementary
Figure 1).
Regions from individual strains that were not present in the
Tohama I reference genome were investigated by BLAST anal-
yses. These regions were also found within other B. pertussis ge-
nomes (BP18323 and CS) or in Bordetella bronchiseptica RB50,
similar to that reported in other studies [26]. Thus, there were
no novel insertions or gene acquisition among outbreak isolates.
Table 3. Single-Nucleotide Polymorphism (SNP) Rates in Vaccine Antigen–Encoding Genes, Compared With Other Cell Surface Protein–
Encoding Genes, Among Strains Isolated in the United Kingdom and Globally During Different Vaccine Eras










Prevaccine era, 1920–1956 5 3× 10−4 7.8× 10−5 2.22× 10−4 2.72 .045
WCV era, 1957–2000 6 4.75× 10−4 5.9× 10−5 4.17× 10−4 6.40 .016
ACV era, 2001–2012 84 1.73× 10−3 1.55× 10−4 1.57× 10−3 8.82 .0004
Global
Prevaccine era, 1920–1956 19 1.45× 10−3 5.85× 10−4 8.62× 10−4 1.44 .012
WCV era, 1957–2000 204 2.62× 10−3 1.01× 10−3 1.61× 10−3 1.56 .002
ACV era, 2001–2012 188 2.91× 10−3 4.23× 10−4 2.49× 10−3 5.41 .0001
Abbreviations: ACV, acellular pertussis vaccine; WCV, whole-cell pertussis vaccine.
a Calculated as the mean SNP density in vaccine antigen–encoding genes minus the mean SNP density in cell surface protein–encoding genes.
b Calculated as [the mean SNP density in vaccine antigen–encoding genes minus the mean SNP density in cell surface protein–encoding genes]/mean overall SNP
density.
c For the difference in SNP rate between vaccine antigen–encoding genes and cell surface protein–encoding genes.
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The resurgence of pertussis in countries with high levels of vac-
cination has caused widespread concern. Among other factors,
B. pertussis evolution away from efﬁcient control by vaccine-
induced immunity has been proposed as a contributor to this.
Recently, whole-genome sequencing was used to deﬁne global
genetic variability among B. pertussis isolates, and it identiﬁed
genetic changes in the B. pertussis population over time [19].
Here, we have analyzed in detail the genomes of UK B. per-
tussis isolates, with an emphasis on strains from the 2012 out-
break. We are the ﬁrst to show that many genetically distinct B.
pertussis strains contributed to this outbreak and, importantly,
that it was not due to the emergence of a novel, hypervirulent
clone or to expansion of an individual lineage. Furthermore,
outbreak strains were genetically very similar to those circulat-
ing during periods when the incidence of pertussis was low.
The ptxP3 type is the dominant clone worldwide, and UK
outbreak strains are also predominantly of this type. Analysis
of global isolates identiﬁed just 19 SNPs as being ptxP3 speciﬁc
[19]. Here, 22 SNPs distinguished ptxP3 strains from ptxP1
strains. However, just 10 of these were common to both sets
of ptxP3-speciﬁc SNPs. If ptxP3 strains have increased ﬁtness
or virulence than older isolates, our analysis suggests that very
few SNPs are responsible for this, or that particular combina-
tions of SNPs are important, only some of which are ptxP3 spe-
ciﬁc. Overall, these data argue against large-scale genetic
changes being behind the recent resurgence in pertussis.
Changes in alleles of the genes encoding vaccine antigens
have been well documented [27], and these ﬁndings support
the hypothesis that selection pressure from ACV-induced im-
munity is a driver of B. pertussis evolution. However, deﬁnitive
studies to demonstrate that allelic variation enhances evasion of
vaccine-mediated immunity are lacking and particularly difﬁ-
cult to perform, because of the inability to conduct studies
with human hosts, and studies using animal models struggle
to detect subtle changes and will not include population-level
effects that are certainly important for selection of variants
among B. pertussis worldwide. Here, we provide compelling ev-
idence that genes encoding ACV antigens are evolving more
rapidly than other cell surface protein–encoding genes (which
we consider the most suitable comparator group), containing
a signiﬁcantly higher frequency of SNPs in each of the vaccine
eras. Interestingly, this was true even in the prevaccine era. It
is likely that, even in the absence of vaccination, the natural
immune response to these antigens creates selective pressure,
particularly for a pathogen that is restricted to the human
respiratory tract. Of particular importance is that we calculated
that ACV antigen–encoding gene evolution rates have increased
signiﬁcantly since the introduction of ACVs, the ﬁrst demon-
stration of this effect. This might suggest that the use of
ACVs has increased selection pressure on ACV antigens, select-
ing for ACV antigen–encoding gene variants. However, we also
calculated that, while the frequency of SMs in ACV antigen–
encoding genes was signiﬁcantly higher in ACV-era strains,
compared with older strains, the frequency of NSMs was on
the edge of signiﬁcance (P = .051). In turn, this suggests that se-
lection pressure from vaccine-mediated immunity is not the
sole driving force for ACV antigen–encoding gene variation.
A different interpretation is that the mutation rate of ACV an-
tigen–encoding genes has increased since the introduction of
ACVs. If synonymous sites are under weak purifying selection
pressure (ie, not perfectly neutral), then there is a lag between a
SNP arising and its elimination by this selection, resulting in an
Table 4. Synonymous and Nonsynonymous Mutation Rates in Vaccine Antigen–Encoding Genes, Compared With Other Cell Surface
Protein–Encoding Genes, Among Strains Isolated Globally During Different Vaccine Eras










Prevaccine era, 1920–1956 19 1.32× 10−4 2.4× 10−4 −1.07× 10−4 −0.45 .627
WCV era, 1957–2000 204 9.66× 10−4 4.23× 10−4 5.43× 10−4 1.26 .045
ACV era, 2001–2012 188 9.68× 10−4 1.76× 10−4 7.92× 10−4 4.20 .011
Nonsynonymous
Prevaccine era, 1920–1956 19 1.18× 10−3 3.40× 10−4 8.38× 10−4 2.38 .006
WCV era, 1957–2000 204 1.96× 10−3 5.83× 10−4 1.37× 10−3 2.28 .002
ACV era, 2001–2012 188 1.95× 10−3 2.38× 10−4 1.71× 10−3 6.48 .0002
Abbreviations: ACV, acellular pertussis vaccine; SNP, single-nucleotide polymorphism; WCV, whole-cell pertussis vaccine.
a Calculated as the mean SNP density in vaccine antigen–encoding genes minus the mean SNP density in cell surface protein–encoding genes.
b Calculated as [the mean SNP density in vaccine antigen–encoding genes minus the mean SNP density in cell surface protein–encoding genes]/mean overall SNP
density.
c For the difference in SNP rate between vaccine antigen–encoding genes and cell surface protein–encoding genes.
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excess of SNPs in the modern era. However, normalizing the
ACV antigen–encoding gene SNP rates by the SNP rates for
all genes within the era largely eliminates this effect (ie, SMs
in cell surface protein–encoding genes should be equally over-
represented in the modern era). However, if SMs in ACV anti-
gen–encoding genes and cell surface protein–encoding genes
are under different intensities of purifying selection, then our
result could be found.
Either way, the more rapid evolution at the protein level (as
determined by NSMs) of ACV proteins, compared with other
cell surface proteins, across all eras suggests that strains will be-
come increasingly mismatched to those used for vaccine pro-
duction, and this could lead to decreased vaccine efﬁcacy over
time. The ACV antigens were chosen on the basis of their im-
munogenicity, but it could be that this property has driven the
relatively high evolution rates of the genes encoding these anti-
gens. Our results raise fresh concerns over the ability of current
ACVs to continue to control disease.
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